

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

New evidence for a genetic contribution to myasthenia gravis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037909
Article Type:	Original research
Date Submitted by the Author:	21-Feb-2020
Complete List of Authors:	<p>Green, Joshua; National Institute on Aging Intramural Research Program, Neuromuscular Diseases Research Unit, Laboratory of Neurogenetics</p> <p>Barohn, Richard; University of Kansas Medical Center, Department of Neurology</p> <p>Bartoccion, Emanuela; Catholic University, Fondazione Policlinico Universitario "A. Gemelli" - I.R.C.C.S., Institute of General Pathology</p> <p>Benetar, Michael; University of Miami, Department of Neurology</p> <p>Blackmore, Derrick; University of Alberta Hospital, Department of Medicine</p> <p>Chaudhry, Vinay; Johns Hopkins School of Medicine, Department of Neurology</p> <p>Chopra, Manisha ; University of North Carolina at Chapel Hill, Department of Neurology</p> <p>Corse, Andrea; Johns Hopkins School of Medicine, Department of Neurology</p> <p>Dimachkie, Mazen M.; University of Kansas Medical Center, Department of Neurology</p> <p>Evoli, Amelia ; Policlinico A. Gemelli IRCSS, Università Cattolica del S. Cuore, Istituto di Neurologia</p> <p>Florence , Julaine ; Washington University School of Medicine in Saint Louis, Department of Neurology</p> <p>Freimer , Miriam ; Ohio State University Medical Center, Department of Neurology</p> <p>Howard, James ; University of North Carolina at Chapel Hill, Department of Neurology</p> <p>Jiwa, Theresa; University of British Columbia, Division of Neurology</p> <p>Kaminski , Henry ; George Washington University</p> <p>Kissel, JT; Ohio State University Medical Center, Department of Neurology</p> <p>Koopman, Wilma; London Health Sciences Centre, Department of Clinical Neurosciences,</p> <p>Lipscomb, Bernadette ; Duke University Medical Center, Department of Neurology</p> <p>Maestri , Michelangelo ; University of Pisa, Department of Neuroscience</p> <p>Marino, Mariapaola ; Catholic University, Fondazione Policlinico Universitario "A. Gemelli" - I.R.C.C.S., Institute of General Pathology</p> <p>Massey, Janice; Duke University Medical Center, Department of Neurology</p> <p>McVey , April ; University of Kansas Medical Center, Department of Neurology</p>

	<p>Mezei , Michelle ; The University of British Columbia, Division of Neurology</p> <p>Muppidi , Srikanth ; Stanford University, Department of Neurology and Neurosciences</p> <p>Nicolle, Michael ; London Health Sciences Centre, Division of Neurology</p> <p>Oger, Joel; The University of British Columbia, Division of Neurology</p> <p>Pascuzzi , Robert ; Indiana University Purdue University at Indianapolis, Department of Neurology</p> <p>Pasnoor , Mamatha ; University of Kansas Medical Center, Department of Neurology</p> <p>Pestronk , Alan ; Washington University School of Medicine in Saint Louis, Department of Neurology</p> <p>Provenzano , Carlo ; Catholic University, Fondazione Policlinico Universitario "A. Gemelli" - I.R.C.C.S, Institute of General Pathology</p> <p>Ricciardi , Roberta ; University of Pisa, Department of Neuroscience</p> <p>Richman, DP; Center for Neuroscience, University of California, Neurology</p> <p>Rowin, Julie ; APAC Centers for Pain Management Wellness and Integrative Neurology</p> <p>Sanders, Donald ; Duke University Medical Center, Department of Neurology</p> <p>Siddiqi , Zaeem ; University of Alberta Hospital, Department of Medicine</p> <p>Soloway, Aimee ; University of Alberta Hospital, Department of Medicine</p> <p>Wolfe, Gil ; State University of New York at Buffalo, Department of Neurology</p> <p>Wulf, Charlie; Washington University School of Medicine in Saint Louis, Department of Neurology</p> <p>Drachman, Daniel ; Johns Hopkins School of Medicine</p> <p>Traynor, Bryan ; National Institute on Aging Intramural Research Program, Neuromuscular Diseases Research Unit, Laboratory of Neurogenetics</p>
Keywords:	<p>EPIDEMIOLOGY, Neuromuscular disease < NEUROLOGY, GENETICS, Neurology < INTERNAL MEDICINE, Neurogenetics < NEUROLOGY</p>

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

New evidence for a genetic contribution to myasthenia gravis

Joshua D. Green, BS; Richard J. Barohn, MD; Emanuela Bartoccion, PhD; Michael Benetar, MD, PhD; Derrick Blackmore, BSc; Vinay Chaudhry, MD; Manisha Chopra, MD; Andrea Corse, MD; Mazen M. Dimachkie, MD; Amelia Evoli, MD; Julaine Florence, PT, MHS, DPT; Miriam Freimer, MD; James F. Howard Jr, MD; Theresa Jiwa; Henry J. Kaminski, MD; John Kissel, MD; Wilma J. Koopman, RN; Bernadette Lipscomb, RN; Michelangelo Maestri, MD; Mariapaola Marino, MD; Janice M. Massey, MD; April McVey, MD; Michelle M. Mezei, MD; Srikanth Muppidi, MD; Michael W. Nicolle, MD; Joel Oger, MD; Mamatha Pasnoor, MD; Alan Pestronk, MD; Carlo Provenzano, MD, PhD; Roberta Ricciardi, MD; David P. Richman, MD; Julie Rowin, MD; Donald B. Sanders, MD; Zaeem Siddiqi, MD; Aimee Soloway, RN; Gil I. Wolfe, MD; Charlie Wulf, BS; Daniel B. Drachman, MD*; and Bryan J. Traynor, MD, PhD*

* These authors contributed equally to the manuscript.

Author Contributions: The study concept and design was proposed by DBD and BJT. The acquisition, analysis, and/or interpretation of data provided done by all authors. The manuscript was drafted by JDG and BJT. Critical revisions and intellectual contributions was provided by all authors. The statistical analysis for this study was provided by JDG.

Affiliations

Joshua D. Green, Neuromuscular Diseases Research Unit, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Porter Neuroscience Research Center, Bethesda, Maryland

1
2
3 Richard J. Barohn, Department of Neurology, University of Kansas Medical Center,
4
5 Kansas City
6

7
8 Emanuela Bartoccion, Institute of General Pathology, Catholic University, Fondazione
9
10 Policlinico Universitario "A. Gemelli" - I.R.C.C.S, Rome, Italy.
11

12 Michael Benetar, Department of Neurology, University of Miami, Miami, Florida
13

14
15 Derrick Blackmore, Department of Medicine, University of Alberta Hospital, Edmonton,
16
17 Alberta, Canada
18

19
20 Vinay Chaudhry, Department of Neurology, Johns Hopkins School of Medicine,
21
22 Baltimore, Maryland
23

24 Manisha Chopra, Department of Neurology, University of North Carolina, Chapel Hill
25

26
27 Andrea Corse, Department of Neurology, Johns Hopkins School of Medicine, Baltimore,
28
29 Maryland
30

31
32 Mazen M. Dimachkie, Department of Neurology, University of Kansas Medical Center,
33
34 Kansas City, Kansas
35

36
37 Amelia Evoli, Istituto di Neurologia, Policlinico A. Gemelli IRCSS, Università Cattolica
38
39 del S. Cuore, Roma, Italy
40

41
42 Julaine Florence, Department of Neurology, Washington University School of Medicine,
43
44 St Louis, Missouri
45

46
47 Miriam Freimer, Department of Neurology, Ohio State University Medical Center,
48
49 Columbus
50

51
52 James F. Howard Jr, Department of Neurology, University of North Carolina, Chapel Hill
53

54
55 Theresa Jiwa, Division of Neurology, University of British Columbia, Vancouver, British
56
57 Columbia, Canada
58
59

1
2
3 Henry J. Kaminski, Department of Neurology, George Washington University,
4
5 Washington, DC
6

7 John Kissel, Department of Neurology, Ohio State University Medical Center, Columbus
8
9

10 Wilma J. Koopman, Department of Clinical Neurosciences, London Health Sciences
11
12 Centre, London, Ontario, Canada
13

14 Bernadette Lipscomb, Department of Neurology, Duke University Medical Center,
15
16 Durham, North Carolina
17

18 Michelangelo Maestri, Department of Neuroscience, Cisanello Hospital, University of
19
20 Pisa, Pisa, Italy
21
22

23 Mariapaola Marino, Institute of General Pathology, Catholic University, Fondazione
24
25 Policlinico Universitario "A. Gemelli" - I.R.C.C.S, Rome, Italy.
26
27

28 Janice M. Massey, Department of Neurology, Duke University Medical Center, Durham,
29
30 North Carolina
31
32

33 April McVey, Department of Neurology, University of Kansas Medical Center, Kansas
34
35 City
36
37

38 Michelle M. Mezei, Division of Neurology, University of British Columbia, Vancouver,
39
40 British Columbia, Canada
41

42 Srikanth Muppidi, Clinical Associate Professor, Dept of Neurology and Neurosciences.
43
44 Stanford University
45

46 Michael W. Nicolle, Department of Clinical Neurosciences, London Health Sciences
47
48 Centre, London, Ontario, Canada
49

50 Joel Oger, Division of Neurology, University of British Columbia, Vancouver, British
51
52 Columbia, Canada
53
54
55
56
57
58
59
60

1
2
3 Robert M. Pascuzzi, Department of Neurology, Indiana University–Purdue University,
4 Indianapolis
5

6
7 Mamatha Pasnoor, Department of Neurology, University of Kansas Medical Center,
8 Kansas City
9

10
11 Alan Pestronk, Department of Neurology, Washington University School of Medicine, St
12 Louis, Missouri
13

14
15 Carlo Provenzano, Institute of General Pathology, Catholic University, Fondazione
16 Policlinico Universitario "A. Gemelli" - I.R.C.C.S, Rome, Italy.
17

18
19 Roberta Ricciardi, Department of Neuroscience, Cisanello Hospital, University of Pisa,
20 Pisa, Italy
21

22
23 David P. Richman, Department of Neurology, University of California, Davis
24

25
26 Julie Rowin, APAC Centers for Pain Management Wellness and Integrative Neurology
27 Westchester, Illinois
28

29
30 Donald B. Sanders, Department of Neurology, Duke University Medical Center,
31 Durham, North Carolina
32

33
34 Zaeem Siddiqi, Department of Medicine, University of Alberta Hospital, Edmonton,
35 Alberta, Canada
36

37
38 Aimee Soloway, Department of Medicine, University of Alberta Hospital, Edmonton,
39 Alberta, Canada
40

41
42 Gil I. Wolfe, Department of Neurology, University at Buffalo Jacobs SMBS, State
43 University of New York, Buffalo
44

45
46 Charlie Wulf, Department of Neurology, Washington University School of Medicine, St
47 Louis, Missouri
48

1
2
3 Daniel Drachman, Department of Neurology, Johns Hopkins School of Medicine,
4
5 Baltimore, Maryland
6

7
8 Bryan J. Traynor, Neuromuscular Diseases Research Unit, Laboratory of
9
10 Neurogenetics, National Institute on Aging, National Institutes of Health, Porter
11
12 Neuroscience Research Center, Bethesda, Maryland
13
14
15

16
17 **Corresponding Author:**

18
19 Bryan J. Traynor MD PhD,
20
21 35 Convent Drive, Room 1A-213, Bethesda, MD 20892-3707.
22
23 *Phone:* 301-451-7606.
24
25
26 traynorb@mail.nih.gov
27
28
29

30
31 **Author Contact Information:**

32
33 Joshua D. Green josh.green@nih.gov
34
35 Richard J. Barohn rbarohn@kumc.edu
36
37 Emanuela Bartoccion ebartoc@gmail.com
38
39 Michael Benetar MBenatar@med.miami.edu
40
41
42 Derrick Blackmore dblackmo@ualberta.ca
43
44 Vinay Chaudhry vchaudh@jhmi.edu
45
46 Manisha Chopra chopram@neurology.unc.edu
47
48
49 Andrea Corse acorse@jhmi.edu
50
51 Mazen M. Dimachkie mdimachkie@kumc.edu
52
53
54 Amelia Evoli amelia.evoli@unicatt.it
55
56
57
58
59
60

1
2
3 Julaine Florence florencej@neuro.wustl.edu
4

5 Miriam Freimer miriam.freimer@osumc.edu
6

7 James F. Howard Jr howardj@neurology.unc.edu
8

9
10 Theresa Jiwa theresajiwa@shaw.ca
11

12 Henry J. Kaminski henryjkaminski@gmail.com
13

14 John Kissel John.Kissel@osumc.edu
15

16 Wilma J. Koopman wkoopman@uwo.ca
17

18 Bernadette Lipscomb btlipscomb@gmail.com
19

20 Michelangelo Maestri michelangelo.mvg@tin.it
21

22 Mariapaola Marino mariapaola.marino@unicatt.it
23

24 Janice M. Massey masse005@mc.duke.edu
25

26 April McVey aprillynnmcvey@gmail.com
27

28 Michelle M. Mezei mezei@mail.ubc.ca
29

30 Srikanth Muppidi muppidis@stanford.edu
31

32 Michael W. Nicolle mnicolle@uwo.ca
33

34 Joel Oger joel.oger@ubc.ca
35

36 Robert M. Pascuzzi rpascuzz@iupui.edu
37

38 Mamatha Pasnoor mpasnoor@kumc.edu
39

40 Alan Pestronk pestronka@neuro.wustl.edu
41

42 Carlo Provenzano carlo.provenzano@unicatt.it
43

44 Roberta Ricciardi r.ricciardi@ao-pisa.toscana.it
45

46 David P. Richman dprichman@ucdavis.edu
47

48 Julie Rowin jrowin@apacgroupe.com
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Donald B. Sanders sande007@mc.duke.edu
4

5 Zaeem Siddiqi zsiddiqi@ualberta.ca
6

7 Aimee Soloway Aimee.Soloway@albertahealthservices.ca
8
9

10 Gil I. Wolfe gilwolfe@buffalo.edu
11

12 Charlie Wulf wulfc@neuro.wustl.edu
13

14 Daniel Drachman dandrac@aol.com
15

16 Bryan J. Traynor traynorb@mail.nih.gov
17
18
19
20

21 Submission Type: **Original Research**
22

23 Title Character count: **60**
24

25 Number of Tables: **2**
26
27

28 Number of Figures: **3**
29

30 Number of References: **22**
31

32 Word count of Abstract: **201**
33
34

35 Word count of Paper: **2020**
36
37
38
39
40
41
42
43

44 **Statistical analysis:** conducted by Joshua Green, BS, and Dr. Bryan Traynor, MD,
45
46 PhD, National Institutes of Health.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives To approximate the rate of familial myasthenia gravis and the coexistence of other autoimmune disorders in the patients and their families.

Design Retrospective cohort study

Setting Clinics across North America

Participants The study included 1,032 patients diagnosed with acetylcholine receptor antibody (AChR)-positive myasthenia gravis

Methods Phenotype information of 1,032 patients diagnosed with acetylcholine receptor antibody (AChR)-positive myasthenia gravis was obtained from clinics at fourteen centers across North America between January 2010 and January 2011. A critical review of the epidemiological literature on the familial rate of myasthenia gravis was also performed.

Results Among 1,032 patients, 58 (5.6%) reported a family history of myasthenia gravis. In comparing the familial and sporadic cohorts, the only feature that was different was the lower age of onset in familial cases. A history of autoimmune diseases was present in 26.6% of patients and in 28.4% of their family members.

Discussion The familial rate of myasthenia gravis was higher than would be expected for a sporadic disease. Furthermore, a high proportion of patients had a personal or family history of autoimmune disease. Taken together, these findings suggest a genetic contribution to the pathogenesis of myasthenia gravis.

ARTICLE SUMMARY

Strengths and limitations of this study

- A strength of this study is that it analyzes a large cohort of myasthenia gravis patients with complete data on each patient, allowing multiple clinical correlations to be made.
- A strength of this study is that standardized criteria were used to diagnose patients with myasthenia gravis, including establishing the specific subtype of the disease for each patient.
- A strength of this study is that the cohort of myasthenia gravis patients was sufficiently large to allow the generation of evidence confirming a genetic contribution to the disease.
- A limitation of this study is the reliance on self-reported family history status for both myasthenia gravis and other autoimmune diseases by the patients.
- A limitation of this study is its retrospective design, which precludes ascertaining additional information from individual patients.

INTRODUCTION

Myasthenia gravis is a rare autoimmune disease that is characterized by antibody-mediated interference with neuromuscular transmission at the neuromuscular junction. Originally, the role for an autoimmune attack against the acetylcholine receptor (AChR) on the postsynaptic side of the neuromuscular junction was recognized.¹ However, over the past decade, additional autoimmune targets have been identified: muscle-specific tyrosine kinase (MuSK), agrin, and lipoprotein receptor-related protein 4 (LRP4).²⁻⁴ All of these proteins play essential roles in maintaining the structure and function of the neuromuscular junction.

Myasthenia gravis manifests clinically with muscle weakness and fatigability. Symptoms of ocular muscle weakness are observed early in 85% of myasthenic patients.⁵ These symptoms include diplopia and/or ptosis. Weakness of the bulbar musculature is observed in 60% of myasthenic patients, with symptoms including dysarthria and/or dysphagia.⁵

A recent literature review of thirty-one epidemiological studies suggests that the annual incidence of myasthenia gravis may range between 3 and 30 cases per million people.⁶ A common theme among myasthenia gravis epidemiological studies is that there is a significant degree of variability between cohorts. For example, a study of a Hong Kong Chinese cohort reported an incidence of 4 per million people per year, whereas a study of an English cohort reported an incidence of 30 per million people per year.^{7, 8} This substantial degree of variability may be the result of inconsistent diagnostic criteria, varying case ascertainment, lack of physician awareness concerning myasthenia gravis, or it may reflect different occurrence across populations.

1
2
3 Historically, adult-onset myasthenia gravis has been regarded as a sporadic
4 disease with only a minimal genetic component.⁹ However, genome-wide association
5 studies, fine-mapping studies, and epidemiological studies of myasthenia gravis
6 suggest a genetic contribution to the disease.^{10, 11} In fact, studies have described
7 myasthenic patients with a family history of myasthenia gravis and/or a family history of
8 autoimmune diseases. In this study, we performed a literature search of the familial rate
9 reported by myasthenia gravis epidemiological studies and, using our cohort of 1,032
10 North American myasthenia gravis patients, approximated the prevalence of familial
11 myasthenia gravis, compared the characteristics of familial disease with sporadic
12 disease, and assessed the co-morbidity of other autoimmune diseases among patients
13 and among their families.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 **METHODS**

32 **Patient ascertainment**

33 Phenotype information of 1,032 patients diagnosed with myasthenia gravis was
34 obtained from myasthenia gravis clinics at fourteen centers across North America
35 between January 2010 and January 2011.¹⁰ Patients were diagnosed by neurologists
36 specializing in myasthenia gravis. Each myasthenia gravis diagnosis was based on
37 standard clinical criteria that included, but was not limited to, weakness, fatigability, and
38 electrophysiological, pharmacological (edrophonium test) and/or serological
39 abnormalities. Inclusion criteria for this study were as follows: confirmed diagnosis of
40 myasthenia gravis, non-Hispanic white ethnicity, and presence of anti-AChR antibodies.
41 Patients with anti-MuSK antibodies were excluded from the study. The LRP4 antibody
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 was discovered after the collection of the cohort was complete. Thus, the LRP4
4
5 antibody status of the patients was not known. Family histories of myasthenia gravis
6
7 and other autoimmune diseases were systematically obtained for each subject using a
8
9 simple structured questionnaire. A positive family history was defined as having a first-
10
11 degree (50% of DNA in common), second-degree (25% of DNA in common), or third-
12
13 degree (12.5% of DNA in common) relative with the disease. DNA samples were
14
15 collected from each subject and used for genetic analyses as previously reported.¹⁰
16
17
18 Patients with genetic forms of myasthenia gravis were not explicitly excluded, though
19
20 none of the cohort was known to have such a mutation.
21
22
23
24
25

26 **Literature review methodology**

27
28 To find studies about the epidemiology of familial myasthenia gravis, the PubMed and
29
30 Medline databases were searched using permutations of search terms: 'epidemiology of
31
32 familial myasthenia gravis', 'epidemiology of myasthenia gravis', and 'heritability of
33
34 myasthenia gravis'. After reviewing thirty-one epidemiology studies between the years
35
36 of 1950 through 2018, only ten studies explicitly referenced the family history of
37
38 myasthenic patients. Five of those papers provided metrics about family members with
39
40 myasthenia gravis.¹²⁻¹⁶
41
42
43
44
45
46

47 **Patient and public involvement statement**

48
49 No patients or members of the public were actively involved with co-producing the
50
51 research presented in this article.
52
53
54
55
56
57
58
59
60

Statement of ethics approval

Written informed consent was obtained from all patients who participated in this study.

Institution review board (IRB) approval was obtained at all participating institutions.

Lead institutes for IRB = National Institutes of Health, protocol 03-AG-N329,

<https://clinicaltrials.gov/ct2/show/NCT02014246>

Data availability

The data, consisting of patient family history of myasthenia gravis and other autoimmune diseases in addition to patient personal history of other autoimmune diseases, are not publicly available because of patient privacy concerns but de-identified participant data are available upon request by contacting the corresponding author. In the interests of scientific rigor, the code used for analysis of the dataset is available on GitHub: <https://github.com/neurogenetics/Familial-Myasthenia-Gravis>.

RESULTS

North American cohort of myasthenia gravis patients

Clinical data were collected from a total of 1,032 patients across fourteen centers in North America and were analyzed in this study. All of the patients had positive anti-AChR antibodies. The mean age of symptom onset in this clinic-based cohort was 53.5 years of age (standard deviation (SD) = 19.4). The female-to-male ratio was 1:1.27. Early-onset disease (< 40 years of age) was observed among 248 (24.0%) of the cohort. Consistent with other reports, nearly one third of the patients in our North American study cohort (305, 29.6%) had undergone thymectomy.

Fifty-eight (5.6%) patients had a family history of myasthenia gravis. Sibling-sibling (31.0%) and parent-child (32.8%) were the most common type of familial relationship, followed by uncle/aunt-nephew/niece (13.8%), cousin-cousin (12.1%) and grandparent-grandchild (5.2%) relationships. Age at symptom onset was slightly younger (50.5 years of age, SD = 19.4) among patients reporting a family history compared to patients without a positive family history (53.7 years, SD = 19.4), though this difference was not statistically significant (p-value = 0.23, Welch's independent two group t-test, figure 1). Approximately one fourth of the familial patients (n = 15) experienced disease prior to the age of 40 (table 1).

Table 1. Comparison of familial and sporadic cases among a cohort of patients diagnosed with myasthenia gravis (n = 1,032)

	Familial	Sporadic	P-value
Number of myasthenia gravis cases (percent)	58 (5.6)	974 (94.4)	-
Mean age of disease onset (years) (standard deviation)	50.5 (19.4)	53.7 (19.4)	0.227
Number of patients with early-onset disease (< 40 years) (percent)	15 (25.9)	233 (23.9)	0.86
Number of females	25 (43.1)	429 (44.0)	0.997

(percent)

A personal history of an autoimmune disease other than myasthenia gravis was reported in 275 (26.6%) of study participants. A total of 293 (28.4%) subjects had a family history of an autoimmune disease. The prevalence of autoimmunity in the general population is ~3-9%, indicating that the rates observed among our myasthenia gravis subjects are significantly increased.¹⁷ A breakdown of the specific autoimmune diseases for both personal history and family history of disease is shown in figure 2A and figure 2B.

The most common autoimmune diseases present concomitantly in myasthenia gravis patients were thyroid disease (n = 118, 11.4%), hematological disease (n = 33, 3.2% consisting of autoimmune hemolytic anemia and autoimmune thrombocytopenic purpura), and rheumatoid arthritis (n=28, 2.7%). This was similar to the rates previously reported by Mao et al (figure 2C).¹⁸

The three most common autoimmune diseases present in the families of myasthenia gravis patients were thyroid disease (n=98, 9.5%), rheumatoid arthritis (n=68, 6.6%), and type 1 diabetes (n=36, 3.5%).

Literature review

Literature review concerning the epidemiology of familial myasthenia gravis identified five studies that discussed the patient's family history of myasthenia gravis with sample sizes that ranged from 264 to 6,638 (table 2).¹²⁻¹⁶ The frequency of familial myasthenia gravis ranged from 0.2% to 7.2% across studies, the upper limit having been reported

based on a Finnish cohort.¹⁵ Among these, three studies reported that familial myasthenia gravis cases had an earlier symptom onset age than the sporadic cases.^{12, 14, 15} Only three studies reported on the patient history of other autoimmune diseases and/or on the family history of other autoimmune diseases.^{12, 14, 15} Among these, thyroid disease, rheumatoid arthritis, systemic lupus erythematosus, and Sjogren's syndrome were the most common other autoimmune diseases reported in patients' personal and/or family histories.^{12, 14, 15}

Table 2. Studies reporting the rate of familial disease in myasthenia gravis.

Source	Origin	Sample size	Familial rate	Study type
12	Taiwan	6,638	0.2%	Population
13	Japan	3,141	0.7%	Population
14	Spain	462	3.5%	Clinic
15	Finland	264	7.2%	Population
16	United States	702	3.8%	Clinic

DISCUSSION

We found the prevalence of familial myasthenia gravis in our North American cohort to be 5.6%. This is comparable to the prevalence reported in other studies, where the frequency ranged from 0.2% to 7.2% of myasthenia gravis patients having a family history of myasthenia gravis depending on the cohort studied. Although the vast

1
2
3 majority of myasthenia gravis cases are still non-familial, a prevalence of 5.6%
4
5 represents a several hundred-fold increase for a disease with an overall prevalence of 1
6
7 in 5-10,000. The two studies of myasthenia gravis based on Asian cohorts reported
8
9 substantially lower rates of familial disease compared to our North American cohort and
10
11 other European cohorts. For example, two studies of Taiwanese (n = 6,638) and
12
13 Japanese (n = 3,141) cohorts reported rates of familial myasthenia gravis at 0.2% and
14
15 0.7%, respectively. Three studies of Spanish, American, and Finnish cohorts reported
16
17 rates of 3.5%, 3.8%, and 7.2% (table 2). The familial rates reported in our cohort of over
18
19 1,000 patients were, as expected, closer in value to the rates reported among European
20
21 and American cohorts. Overall, these data suggest that there is population variation in
22
23 the inheritance of myasthenia gravis that warrants further study to identify the genetic
24
25 contribution to disease risk.
26
27
28
29

30
31 For a number of genetic diseases, a family history is often associated with an
32
33 earlier age of onset.^{19, 20} Three of the studies in the literature review reported that this
34
35 was also true of myasthenia gravis.^{12, 14, 15} Interestingly, we also observed an earlier
36
37 onset age in the familial cases (50.5 years of age) compared to the non-familial (53.7
38
39 years of age) cases in our cohort (table 1). However, this difference was not significant,
40
41 a finding that is consistent with previous reports.
42
43

44
45 Another notable feature of our cohort is that males had a slightly higher
46
47 prevalence of familial myasthenia gravis compared to the females (1:1.32), suggesting
48
49 that there might be sex-specific differences in the occurrence of familial versus sporadic
50
51 disease. This observation may reflect the different age distribution of myasthenia gravis
52
53 cases in males versus females observed across all myasthenia gravis cases (mean
54
55
56
57
58
59
60

1
2
3 onset age for females = 45.6; mean onset age for males = 59.8). Indeed, our previous
4 genome-wide association study of myasthenia gravis indicated that the genetic
5 architecture was different among younger and older age groups.¹⁰
6
7

8
9
10 Myasthenia gravis is an immunological disorder and, generally speaking,
11 autoimmune diseases are known to have heritable components.²¹ Likewise,
12 approximately one-third of our cohort had a personal history and/or a family history of
13 another autoimmune disease, which is much higher than the prevalence of 3-9%, which
14 has been historically reported in the general population.¹⁷ We observed that familial
15 myasthenia gravis were more likely to have a personal history of autoimmune disease
16 than the sporadic cohort. Similar to previous reports, we found thyroid disease,
17 rheumatoid arthritis, systemic lupus erythematosus, and type 1 diabetes to be the most
18 commonly identified comorbidities (figure 2C).^{18, 21} Interestingly, the frequency of thyroid
19 disease in this cohort (11.4%) is similar to the frequency range of thyroid disease
20 reported in a study by Kiessling et al.²² The increased prevalence of familial myasthenia
21 gravis and increased prevalence of other autoimmune disorders both suggest that these
22 autoimmune diseases may share a common predisposition that may be genetic in
23 origin.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 Our analyses provide evidence of a genetic contribution to myasthenia gravis
43 based on the higher than expected rate of familial disease observed among our North
44 American patient cohort, as well as the co-occurrence of autoimmune diseases known
45 to have a genetic basis among this population. More work needs to be done to further
46 elucidate the genetic etiology of this archetypal autoimmune disease.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGEMENTS

This work was supported in part by the Intramural Research Programs of the National Institutes of Health National Institute on Aging (Z01-AG000949-02). The work was also supported by the Myasthenia Gravis Foundation (Drs Drachman and Traynor), a generous bequest by Geraldine Weinrib, and a gift from Philip Swift. Support was provided by Mr. and Mrs. Don Brandon and the Department of Neurology, University of Kansas Medical Center. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. We thank the patients and research participants who contributed samples for this study.

Competing interests

Mr. Green none declared.

Dr. Barohn served as a consultant for NuFactor and Momenta Pharmaceutical and receives research support from PTC Therapeutics, Ra Pharma, Orphazyme, Sanofi Genzyme, FDA OOPD, NIH, and PCORI.

Dr. Bartoccion none declared.

Dr. Benetar reports grant support from Muscular Dystrophy Association, ALS Association, ALS Recovery Fund, Kimmelman Estate, Target ALS, Eli Lilly & Company, and the National Institutes of Health (NIH) during the conduct of the study. He also reports grant support from FDA, CDC, and DOD; research support from Alexion

1
2
3 Pharmaceuticals, UCB, Cytokinetics, Neuraltus, Biogen and Orphazyme A/S; and
4
5 personal fees from NMD Pharma, Ra Pharmaceuticals, Mitsubishi-Tanabe, Avexis,
6
7 UCB and Denali outside the submitted work.

8
9
10 Mr. Blackmore none declared

11
12 Dr. Chaudhry served as a consultant for review and expert testimony for the
13
14 Department of Health and Human Services and the Department of Justice under the
15
16 Vaccine Injury and Compensation Program. Dr. Chaudhry has received royalty for total
17
18 neuropathy score (TNS) patented (through Johns Hopkins University) for license of TNS
19
20 use from AstraZeneca, Genentech, Seattle Genetics, Calithera Biosciences, Inc,
21
22 Merrimack Pharmaceuticals, Inc., Levicept, and Acetylon Pharmaceuticals, Inc.

23
24
25 Dr. Chopra none declared.

26
27
28 Dr. Corse none declared.

29
30
31 Dr. Dimachkie recently served as a consultant or on the speaker's bureau for Alnylam,
32
33 Audentes, CSL-Behring, Sanofi Genzyme, Momenta, NuFactor, RMS Medical, Shire
34
35 Takeda and Terumo. Dr. Dimachkie received grants from Alexion, Alnylam
36
37 Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, CSL-Behring,
38
39 FDA/OPD, GlaxoSmithKline, Genentech, Grifols, MDA, NIH, Novartis, Genzyme,
40
41 Octapharma, Orphazyme, UCB Biopharma, Viomed and TMA.

42
43
44 Dr. Evoli was a member of the advisory board for Alexion, a scientific award jury
45
46 member for Grifols and safety data monitor for UCB.

47
48
49 Dr. Florence none declared.

50
51
52 Dr. Freimer has received honoraria for serving on advisory boards for ARGNX pharma,
53
54 Alexion. Dr. Freimer also has research support from Catalyyst, Ra pharma, Amicus,

1
2
3 Orphazyme, Alexion, Momenta and Alnylum.
4

5 Dr. Howard reports research support and grants from Alexion Pharmaceuticals, argenx
6
7 BVBA, Centers for Disease Control and Prevention, Muscular Dystrophy Association,
8
9 NIH (including the National Institute of Neurologic Disorders and Stroke and the
10
11 National Institute of Arthritis and Musculoskeletal and Skin Disease), PCORI (Patient-
12
13 Centered Outcomes Research Institute), and Ra Pharmaceuticals; and nonfinancial
14
15 support from Alexion Pharmaceuticals, argenx BVBA, Ra Pharmaceuticals, and
16
17 Toleranzia.
18
19

20
21 Dr. Jiwa none declared.
22

23
24 Dr. Kaminski is funded by the Muscular Dystrophy Association (508240) and by NIH
25
26 grant U54NS115054; is a consultant for Alnylam Pharmaceuticals, Ra Pharmaceuticals,
27
28 and UCB Pharmaceuticals; and is CEO of ARC Biotechnology, LLC, which receives
29
30 support from the NIH (R41NS110331). He serves on the Editorial Board of Experimental
31
32 Neurology.
33

34
35 Dr. Kissel none declared.
36

37
38 Ms. Koopman none declared.
39

40
41 Ms. Lipscomb none declared.
42

43
44 Dr. Maestri none declared.
45

46
47 Dr. Marino none declared.
48

49
50 Dr. Massey none declared
51

52
53 Dr. McVey none declared.
54

55
56 Dr. Mezei has received honoraria as a speaker and/or moderator from Alnylam, Akcea,
57
58 Pfizer and CSL Behring. She has served on Advisory Boards for Pfizer, Alnylam and
59
60

1
2
3 Akcea. She serves as an investigator for clinical trials with Alnylam and Biogen.

4
5 Dr. Muppidi has served on advisory board meetings for Alexion and argenx.

6
7 Dr. Nicolle none declared.

8
9 Dr. Oger none declared.

10
11 Dr. Pascuzzi none declared.

12
13 Dr. Pasnoor served on advisory board for CSL Behring, Alexion pharmaceuticals,
14
15 Argenx Pharmaceuticals and has been consultant for Momenta Pharmaceuticals.

16
17 Dr. Pestronk none declared.

18
19 Dr. Provenzano none declared.

20
21 Dr. Ricciardi none declared.

22
23 Dr. Richman receives research funding from a Sponsored Research Agreement from
24
25 Cabaletta Bioscience.

26
27 Dr. Rowin none declared.

28
29 Dr. Sanders none declared.

30
31 Dr. Siddiqi none declared.

32
33 Ms. Soloway none declared

34
35 Dr. Wolfe none declared.

36
37 Dr. Wulf none declared.

38
39 Dr. Drachman none declared.

40
41 Dr. Traynor holds an American and European Union patent on the clinical testing and
42
43 therapeutic intervention for the hexanucleotide repeat expansion of C9orf72. Has
44
45 received research grants from The Myasthenia Gravis Foundation, the Robert Packard
46
47 Center for ALS Research, the ALS Association (ALSA), the Italian Football Federation
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 (FIGC), the Center for Disease Control and Prevention (CDC), the Muscular Dystrophy
4 Association (MDA), Merck Inc., and Microsoft Research. Dr. Traynor receives funding
5 through the Intramural Research Program at the National Institutes of Health.
6
7
8
9

10 **Funding**

11
12 Study funding by the National Institutes of Health Intramural Research Program. The
13 work was also supported by the Myasthenia Gravis Foundation (Drs Drachman and
14 Traynor), a generous bequest by Geraldine Weinrib, and a gift from Philip Swift. Support
15 was provided by Mr. and Mrs. Don Brandon and the Department of Neurology,
16 University of Kansas Medical Center.
17
18
19
20
21
22
23
24
25

26 **References**

- 27
28
29 1. Fambrough DM, Drachman DB, Satyamurti S. Neuromuscular
30 junction in myasthenia gravis: decreased acetylcholine receptors. *Science* 1973;
31 182:293-295.
32
33
34
35 2. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-
36 antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis
37 without acetylcholine receptor antibodies. *Nat Med* 2001;7:365-368.
38
39
40
41 3. Gasperi C, Melms A, Schoser B, et al. Anti-agrin autoantibodies in myasthenia
42 gravis. *Neurology* 2014;82:1976-1983.
43
44
45
46 4. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density
47 lipoprotein receptor-related protein 4 in myasthenia gravis. *Ann Neurol* 2011;69:418-
48 422.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 5. Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia
4
5 gravis: a review. *Autoimmune Dis* 2012;2012:874680.
- 6
7 6. McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia gravis: a
8
9 systematic literature review. *Neuroepidemiology* 2010;34:171-183.
- 10
11 7. Yu YL, Hawkins BR, Ip MS, Wong V, Woo E. Myasthenia gravis in Hong Kong
12
13 Chinese. 1. Epidemiology and adult disease. *Acta Neurol Scand* 1992;86:113-119.
- 14
15 8. MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and
16
17 lifetime prevalence of neurological disorders in a prospective community-based study in
18
19 the UK. *Brain* 2000;123 (Pt 4):665-676.
- 20
21 9. Spillane J, Higham E, Kullmann DM. Myasthenia gravis. *BMJ* 2012;345:e8497.
- 22
23 10. Renton AE, Pliner HA, Provenzano C, et al. A genome-wide association study of
24
25 myasthenia gravis. *JAMA Neurol* 2015;72:396-404.
- 26
27 11. Giraud M, Vandiedonck C, Garchon HJ. Genetic factors in autoimmune
28
29 myasthenia gravis. *Ann N Y Acad Sci* 2008;1132:180-192.
- 30
31 12. Liu FC, Kuo CF, See LC, Tsai HI, Yu HP. Familial aggregation of myasthenia
32
33 gravis in affected families: a population-based study. *Clin Epidemiol* 2017;9:527-535.
- 34
35 13. Murai H, Yamashita N, Watanabe M, et al. Characteristics of myasthenia gravis
36
37 according to onset-age: Japanese nationwide survey. *J Neurol Sci* 2011;305:97-102.
- 38
39 14. Salvado M, Canela M, Ponseti JM, et al. Study of the prevalence of familial
40
41 autoimmune myasthenia gravis in a Spanish cohort. *J Neurol Sci* 2016;360:110-114.
- 42
43 15. Pirskanen R. Genetic aspects in myasthenia gravis. A family study of 264 Finnish
44
45 patients. *Acta Neurol Scand* 1977;56:365-388.
- 46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 16. Namba T, Brunner NG, Brown SB, Muguruma M, Grob D. Familial myasthenia
4
5 gravis. Report of 27 patients in 12 families and review of 164 patients in 73 families.
6
7 Arch Neurol 1971;25:49-60.
8
9
- 10 17. Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of
11
12 autoimmune diseases: improved prevalence estimates and understanding of clustering
13
14 of diseases. J Autoimmun 2009;33:197-207.
15
16
- 17 18. Mao ZF, Yang LX, Mo XA, et al. Frequency of autoimmune diseases in
18
19 myasthenia gravis: a systematic review. Int J Neurosci 2011;121:121-129.
20
21
- 22 19. Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal
23
24 dominant Alzheimer disease: a systematic review and meta-analysis. Neurology
25
26 2014;83:253-260.
27
- 28 20. Kharazmi E, Fallah M, Sundquist K, Hemminki K. Familial risk of early and late
29
30 onset cancer: nationwide prospective cohort study. BMJ 2012;345:e8076.
31
32
- 33 21. Ceccarelli F, Agmon-Levin N, Perricone C. Genetic Factors of Autoimmune
34
35 Diseases. J Immunol Res 2016;2016:1-2.
36
37
- 38 22. Kiessling WR, Finke R, Kotulla P, Schleusener H. Circulating TSH-binding
39
40 inhibiting immunoglobulins in myasthenia gravis. Acta Endocrinol (Copenh)
41
42 1982;101:41-46.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figures

Figure 1.

Symptom-onset age distribution of sporadic and familial cases. The density represents the relative probability of myasthenia gravis at each age point.


Figure 2.

Autoimmune diseases in a cohort of 1,032 patients with myasthenia gravis. (A)

Occurrence of autoimmune diseases among patients with myasthenia (n = 275). (B)

Occurrence of autoimmune diseases among familial relatives of patients with



myasthenia gravis (n = 293). (C) Comparisons of autoimmune diseases among patients with myasthenia gravis and among relatives. Size of circles represent the percentage previously reported by Mao et al.¹⁸




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

A. Personal history of autoimmune diseases

B. Family history of autoimmune diseases



C. Relationships between personal and family histories of autoimmune diseases



STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	7-8
Introduction			10-11
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	10-11
Objectives	3	State specific objectives, including any prespecified hypotheses	11
Methods			11-13
Study design	4	Present key elements of study design early in the paper	11
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	11-13
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	11
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	11-13
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	11-13
Bias	9	Describe any efforts to address potential sources of bias	11-13
Study size	10	Explain how the study size was arrived at	11-13
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	11-13
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	14-15
		(b) Describe any methods used to examine subgroups and interactions	14-15
		(c) Explain how missing data were addressed	14-15
		(d) If applicable, explain how loss to follow-up was addressed	14-15
		(e) Describe any sensitivity analyses	NA
Results			13-15

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7,11,14
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	13
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Report numbers of outcome events or summary measures over time	13-15
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13-15
		(b) Report category boundaries when continuous variables were categorized	13-15
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	13-15
Discussion			16-18
Key results	18	Summarise key results with reference to study objectives	16-18
Limitations			17-18
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17-18
Generalisability	21	Discuss the generalisability (external validity) of the study results	17-18
Other information			NA
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	23

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037909.R1
Article Type:	Original research
Date Submitted by the Author:	29-May-2020
Complete List of Authors:	<p>Green, Joshua; National Institute on Aging Intramural Research Program, Neuromuscular Diseases Research Unit, Laboratory of Neurogenetics</p> <p>Barohn, Richard; University of Kansas Medical Center, Department of Neurology</p> <p>Bartoccion, Emanuela; Catholic University, Fondazione Policlinico Universitario "A. Gemelli" - I.R.C.C.S, Institute of General Pathology</p> <p>Benetar, Michael; University of Miami, Department of Neurology</p> <p>Blackmore, Derrick; University of Alberta Hospital, Department of Medicine</p> <p>Chaudhry, Vinay; Johns Hopkins School of Medicine, Department of Neurology</p> <p>Chopra, Manisha ; University of North Carolina at Chapel Hill, Department of Neurology</p> <p>Corse, Andrea; Johns Hopkins School of Medicine, Department of Neurology</p> <p>Dimachkie, Mazen M.; University of Kansas Medical Center, Department of Neurology</p> <p>Evoli, Amelia ; Policlinico A. Gemelli IRCSS, Università Cattolica del S. Cuore, Istituto di Neurologia</p> <p>Florence , Julaine ; Washington University School of Medicine in Saint Louis, Department of Neurology</p> <p>Freimer , Miriam ; Ohio State University Medical Center, Department of Neurology</p> <p>Howard, James ; University of North Carolina at Chapel Hill, Department of Neurology</p> <p>Jiwa, Theresa; University of British Columbia, Division of Neurology</p> <p>Kaminski , Henry ; George Washington University</p> <p>Kissel, JT; Ohio State University Medical Center, Department of Neurology</p> <p>Koopman, Wilma; London Health Sciences Centre, Department of Clinical Neurosciences,</p> <p>Lipscomb, Bernadette ; Duke University Medical Center, Department of Neurology</p> <p>Maestri , Michelangelo ; University of Pisa, Department of Neuroscience</p> <p>Marino, Mariapaola ; Catholic University, Fondazione Policlinico Universitario "A. Gemelli" - I.R.C.C.S., Institute of General Pathology</p> <p>Massey, Janice; Duke University Medical Center, Department of Neurology</p>

	<p>McVey , April ; University of Kansas Medical Center, Department of Neurology</p> <p>Mezei , Michelle ; The University of British Columbia, Division of Neurology</p> <p>Muppidi , Srikanth ; Stanford University, Department of Neurology and Neurosciences</p> <p>Nicolle, Michael ; London Health Sciences Centre, Division of Neurology</p> <p>Oger, Joel; The University of British Columbia, Division of Neurology</p> <p>Pascuzzi , Robert ; Indiana University Purdue University at Indianapolis, Department of Neurology</p> <p>Pasnoor , Mamatha ; University of Kansas Medical Center, Department of Neurology</p> <p>Pestronk , Alan ; Washington University School of Medicine in Saint Louis, Department of Neurology</p> <p>Provenzano , Carlo ; Catholic University, Fondazione Policlinico Universitario "A. Gemelli" - I.R.C.C.S, Institute of General Pathology</p> <p>Ricciardi , Roberta ; University of Pisa, Department of Neuroscience</p> <p>Richman, DP; Center for Neuroscience, University of California, Neurology</p> <p>Rowin, Julie ; APAC Centers for Pain Management Wellness and Integrative Neurology</p> <p>Sanders, Donald ; Duke University Medical Center, Department of Neurology</p> <p>Siddiqi , Zaeem ; University of Alberta Hospital, Department of Medicine</p> <p>Soloway, Aimee ; University of Alberta Hospital, Department of Medicine</p> <p>Wolfe, Gil ; State University of New York at Buffalo, Department of Neurology</p> <p>Wulf, Charlie; Washington University School of Medicine in Saint Louis, Department of Neurology</p> <p>Drachman, Daniel ; Johns Hopkins School of Medicine</p> <p>Traynor, Bryan ; National Institute on Aging Intramural Research Program, Neuromuscular Diseases Research Unit, Laboratory of Neurogenetics</p>
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Neurology
Keywords:	EPIDEMIOLOGY, Neuromuscular disease < NEUROLOGY, GENETICS, Neurology < INTERNAL MEDICINE, Neurogenetics < NEUROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 Epidemiological evidence for a hereditary contribution to myasthenia gravis: a
4 retrospective cohort study of patients from North America
5
6
7
8
9

10 Joshua D. Green, BS; Richard J. Barohn, MD; Emanuela Bartoccion, PhD; Michael
11 Benetar, MD, PhD; Derrick Blackmore, BSc; Vinay Chaudhry, MD; Manisha Chopra,
12 MD; Andrea Corse, MD; Mazen M. Dimachkie, MD; Amelia Evoli, MD; Julaine Florence,
13 PT, MHS, DPT; Miriam Freimer, MD; James F. Howard Jr, MD; Theresa Jiwa; Henry J.
14 Kaminski, MD; John Kissel, MD; Wilma J. Koopman, RN; Bernadette Lipscomb, RN;
15 Michelangelo Maestri, MD; Mariapaola Marino, MD; Janice M. Massey, MD; April McVey,
16 MD; Michelle M. Mezei, MD; Srikanth Muppidi, MD; Michael W. Nicolle, MD; Joel Oger,
17 MD; Mamatha Pasnoor, MD; Alan Pestronk, MD; Carlo Provenzano, MD, PhD; Roberta
18 Ricciardi, MD; David P. Richman, MD; Julie Rowin, MD; Donald B. Sanders, MD;
19 Zaeem Siddiqi, MD; Aimee Soloway, RN; Gil I. Wolfe, MD; Charlie Wulf, BS; Daniel B.
20 Drachman, MD*; and Bryan J. Traynor, MD, PhD*
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 * These authors contributed equally to the manuscript.
36
37
38
39

40 **Author Contributions:** The study concept and design were proposed by DBD and BJT.
41 The acquisition, analysis, and/or interpretation of data provided done by all authors. The
42 manuscript was drafted by JDG and BJT. Critical revisions, intellectual contributions,
43 and final approval were provided by DBD, RJB, EB, MB, DB, VC, MC, AC, MD, AE, JF,
44 MF, JH, TJ, HJK, JK, WJK, BL, MM, MM, JMM, AM, MM, SM, MN, JO, MP, AP, CP,
45 RR, DR, JR, DBS, ZS, AS, GIW, and CW. The statistical analysis for this study was
46 provided by JDG.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Affiliations

Joshua D. Green, Neuromuscular Diseases Research Unit, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Porter Neuroscience Research Center, Bethesda, Maryland

Richard J. Barohn, Department of Neurology, University of Kansas Medical Center, Kansas City

Emanuela Bartoccion, Institute of General Pathology, Catholic University, Fondazione Policlinico Universitario "A. Gemelli" - I.R.C.C.S, Rome, Italy.

Michael Benetar, Department of Neurology, University of Miami, Miami, Florida

Derrick Blackmore, Department of Medicine, University of Alberta Hospital, Edmonton, Alberta, Canada

Vinay Chaudhry, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland

Manisha Chopra, Department of Neurology, University of North Carolina, Chapel Hill

Andrea Corse, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland

Mazen M. Dimachkie, Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas

Amelia Evoli, Istituto di Neurologia, Policlinico A. Gemelli IRCSS, Università Cattolica del S. Cuore, Roma, Italy

Julaine Florence, Department of Neurology, Washington University School of Medicine,

1
2
3 St Louis, Missouri

4
5 Miriam Freimer, Department of Neurology, Ohio State University Medical Center,
6
7
8 Columbus

9
10 James F. Howard Jr, Department of Neurology, University of North Carolina, Chapel Hill

11
12 Theresa Jiwa, Division of Neurology, University of British Columbia, Vancouver, British
13
14 Columbia, Canada

15
16 Henry J. Kaminski, Department of Neurology, George Washington University,
17
18 Washington, DC

19
20 John Kissel, Department of Neurology, Ohio State University Medical Center, Columbus

21
22 Wilma J. Koopman, Department of Clinical Neurosciences, London Health Sciences
23
24 Centre, London, Ontario, Canada

25
26 Bernadette Lipscomb, Department of Neurology, Duke University Medical Center,
27
28 Durham, North Carolina

29
30 Michelangelo Maestri, Department of Neuroscience, Cisanello Hospital, University of
31
32 Pisa, Pisa, Italy

33
34 Mariapaola Marino, Institute of General Pathology, Catholic University, Fondazione
35
36 Policlinico Universitario "A. Gemelli" - I.R.C.C.S, Rome, Italy.

37
38 Janice M. Massey, Department of Neurology, Duke University Medical Center, Durham,
39
40 North Carolina

41
42 April McVey, Department of Neurology, University of Kansas Medical Center, Kansas
43
44 City

45
46 Michelle M. Mezei, Division of Neurology, University of British Columbia, Vancouver,
47
48 British Columbia, Canada

1
2
3 Srikanth Muppidi, Clinical Associate Professor, Dept of Neurology and Neurosciences.
4
5 Stanford University
6

7 Michael W. Nicolle, Department of Clinical Neurosciences, London Health Sciences
8
9 Centre, London, Ontario, Canada
10

11
12 Joel Oger, Division of Neurology, University of British Columbia, Vancouver, British
13
14 Columbia, Canada
15

16
17 Robert M. Pascuzzi, Department of Neurology, Indiana University–Purdue University,
18
19 Indianapolis
20

21
22 Mamatha Pasnoor, Department of Neurology, University of Kansas Medical Center,
23
24 Kansas City
25

26
27 Alan Pestronk, Department of Neurology, Washington University School of Medicine, St
28
29 Louis, Missouri
30

31
32 Carlo Provenzano, Institute of General Pathology, Catholic University, Fondazione
33
34 Policlinico Universitario "A. Gemelli" - I.R.C.C.S, Rome, Italy.
35

36
37 Roberta Ricciardi, Department of Neuroscience, Cisanello Hospital, University of Pisa,
38
39 Pisa, Italy
40

41
42 David P. Richman, Department of Neurology, University of California, Davis
43

44
45 Julie Rowin, APAC Centers for Pain Management Wellness and Integrative Neurology
46
47 Westchester, Illinois
48

49
50 Donald B. Sanders, Department of Neurology, Duke University Medical Center,
51
52 Durham, North Carolina
53

54
55 Zaeem Siddiqi, Department of Medicine, University of Alberta Hospital, Edmonton,
56
57 Alberta, Canada
58
59

1
2
3 Aimee Soloway, Department of Medicine, University of Alberta Hospital, Edmonton,
4
5 Alberta, Canada
6

7
8 Gil I. Wolfe, Department of Neurology, University at Buffalo Jacobs SMBS, State
9
10 University of New York, Buffalo
11

12
13 Charlie Wulf, Department of Neurology, Washington University School of Medicine, St
14
15 Louis, Missouri
16

17
18 Daniel Drachman, Department of Neurology, Johns Hopkins School of Medicine,
19
20 Baltimore, Maryland
21

22
23 Bryan J. Traynor, Neuromuscular Diseases Research Unit, Laboratory of
24
25 Neurogenetics, National Institute on Aging, National Institutes of Health, Porter
26
27 Neuroscience Research Center, Bethesda, Maryland
28
29

30
31 **Corresponding Author:**
32

33 Bryan J. Traynor MD PhD,
34

35 35 Convent Drive, Room 1A-213, Bethesda, MD 20892-3707.
36

37 *Phone:* 301-451-7606.
38

39 traynorb@mail.nih.gov
40
41
42
43

44
45 **Author Contact Information:**
46

47 Joshua D. Green josh.green@nih.gov
48

49 Richard J. Barohn rbarohn@kumc.edu
50

51 Emanuela Bartoccion ebartoc@gmail.com
52

53
54 Michael Benetar MBenatar@med.miami.edu
55
56
57
58
59

1
2
3 Derrick Blackmore dblackmo@ualberta.ca
4
5 Vinay Chaudhry vchaudh@jhmi.edu
6
7 Manisha Chopra chopram@neurology.unc.edu
8
9
10 Andrea Corse acorse@jhmi.edu
11
12 Mazen M. Dimachkie mdimachkie@kumc.edu
13
14 Amelia Evoli amelia.evoli@unicatt.it
15
16
17 Julaine Florence florencej@neuro.wustl.edu
18
19 Miriam Freimer miriam.freimer@osumc.edu
20
21 James F. Howard Jr howardj@neurology.unc.edu
22
23
24 Theresa Jiwa theresajiwa@shaw.ca
25
26 Henry J. Kaminski henrykaminski@gmail.com
27
28 John Kissel John.Kissel@osumc.edu
29
30
31 Wilma J. Koopman wkoopman@uwo.ca
32
33 Bernadette Lipscomb btlipscomb@gmail.com
34
35 Michelangelo Maestri michelangelo.mvg@tin.it
36
37 Mariapaola Marino mariapaola.marino@unicatt.it
38
39
40 Janice M. Massey masse005@mc.duke.edu
41
42 April McVey aprillynnmcvey@gmail.com
43
44 Michelle M. Mezei mezei@mail.ubc.ca
45
46 Srikanth Muppidi muppidis@stanford.edu
47
48
49 Michael W. Nicolle mnicolle@uwo.ca
50
51 Joel Oger joel.oger@ubc.ca
52
53 Robert M. Pascuzzi rpascuzz@iupui.edu
54
55
56
57
58
59
60

1
2
3 Mamatha Pasnoor mpasnoor@kumc.edu
4

5 Alan Pestronk pestronka@neuro.wustl.edu
6

7 Carlo Provenzano carlo.provenzano@unicatt.it
8

9
10 Roberta Ricciardi r.ricciardi@ao-pisa.toscana.it
11

12 David P. Richman dprichman@ucdavis.edu
13

14 Julie Rowin jrowin@apacgroupe.com
15

16 Donald B. Sanders sande007@mc.duke.edu
17

18 Zaeem Siddiqi zsiddiqi@ualberta.ca
19

20 Aimee Soloway Aimee.Soloway@albertahealthservices.ca
21

22 Gil I. Wolfe gilwolfe@buffalo.edu
23

24 Charlie Wulf wulfc@neuro.wustl.edu
25

26 Daniel Drachman dandrac@aol.com
27

28 Bryan J. Traynor traynorb@mail.nih.gov
29
30
31
32
33
34

35 Submission Type: **Original Research**
36

37 Title Character count: **136**
38

39 Number of Tables: **3**
40

41 Number of Figures: **2**
42

43 Number of References: **21**
44

45 Word count of Abstract: **169**
46

47 Word count of Paper: **2097**
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Statistical analysis:** conducted by Joshua Green, BS, and Dr. Bryan Traynor, MD,
4
5 PhD, National Institutes of Health.
6
7
8
9
10
11
12
13
14
15
16

17 **ABSTRACT**

18
19 **Objectives** To approximate the rate of familial myasthenia gravis and the coexistence
20
21 of other autoimmune disorders in the patients and their families.
22

23
24 **Design** Retrospective cohort study
25

26
27 **Setting** Clinics across North America
28

29
30 **Participants** The study included 1,032 patients diagnosed with acetylcholine receptor
31
32 antibody (AChR)-positive myasthenia gravis

33
34 **Methods** Phenotype information of 1,032 patients diagnosed with acetylcholine
35
36 receptor antibody (AChR)-positive myasthenia gravis was obtained from clinics at
37
38 fourteen centers across North America between January 2010 and January 2011. A
39
40 critical review of the epidemiological literature on the familial rate of myasthenia gravis
41
42 was also performed.
43

44
45 **Results** Among 1,032 patients, 58 (5.6%) reported a family history of myasthenia
46
47 gravis. A history of autoimmune diseases was present in 26.6% of patients and in
48
49 28.4% of their family members.
50

51
52 **Discussion** The familial rate of myasthenia gravis was higher than would be expected
53
54 for a sporadic disease. Furthermore, a high proportion of patients had a personal or
55
56
57
58
59
60

1
2
3 family history of autoimmune disease. Taken together, these findings suggest a genetic
4
5 contribution to the pathogenesis of myasthenia gravis.
6
7
8
9
10

11 12 **ARTICLE SUMMARY**

13 14 **Strengths and limitations of this study**

- 15
16
17 • A strength of this study is that it analyzes a large cohort of myasthenia gravis
18 patients with complete data on each patient, allowing multiple clinical correlations
19 to be made.
20
21
- 22
23
24 • A strength of this study is that standardized criteria were used to diagnose
25 patients with myasthenia gravis, including establishing the specific subtype of the
26 disease for each patient.
27
28
- 29
30
31 • A strength of this study is that the cohort of myasthenia gravis patients was
32 sufficiently large to allow the generation of evidence confirming a genetic
33 contribution to the disease.
34
35
- 36
37
38 • A limitation of this study is the reliance on self-reported family history status for
39 both myasthenia gravis and other autoimmune diseases by the patients.
40
41
- 42
43 • A limitation of this study is its retrospective design, which precludes ascertaining
44 additional information from individual patients.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Myasthenia gravis is a rare autoimmune disease that is characterized by antibody-mediated interference with neuromuscular transmission at the neuromuscular junction. Originally, the role for an autoimmune attack against the acetylcholine receptor (AChR) on the postsynaptic side of the neuromuscular junction was recognized.¹ However, over the past decade, additional autoimmune targets have been identified: muscle-specific tyrosine kinase (MuSK), agrin, and lipoprotein receptor-related protein 4 (LRP4).²⁻⁴ All of these proteins play essential roles in maintaining the structure and function of the neuromuscular junction.

Myasthenia gravis manifests clinically with muscle weakness and fatigability. Symptoms of ocular muscle weakness are observed early in 85% of myasthenic patients.⁵ These symptoms include diplopia and/or ptosis. Weakness of the bulbar musculature is observed in 60% of myasthenic patients, with symptoms including dysarthria and/or dysphagia.⁵

A recent literature review of thirty-one epidemiological studies suggests that the annual incidence of myasthenia gravis may range between 3 and 30 cases per million people.⁶ A common theme among myasthenia gravis epidemiological studies is that there is a significant degree of variability between cohorts. For example, a study of a Hong Kong Chinese cohort reported an incidence of 4 per million people per year, whereas a study of an English cohort reported an incidence of 30 per million people per year.^{7, 8} This substantial degree of variability may be the result of inconsistent diagnostic criteria, varying case ascertainment, lack of physician awareness concerning myasthenia gravis, or it may reflect different occurrence across populations.

1
2
3 Historically, adult-onset myasthenia gravis has been regarded as a sporadic
4 disease with only a minimal genetic component.⁹ However, genome-wide association
5 studies, fine-mapping studies, and epidemiological studies of myasthenia gravis
6 suggest a genetic contribution to the disease.^{10, 11} In fact, studies have described
7 myasthenic patients with a family history of myasthenia gravis and/or a family history of
8 autoimmune diseases.¹²⁻¹⁶ In this study, we performed a literature search of the familial
9 rate reported by myasthenia gravis epidemiological studies and, using our cohort of
10 1,032 North American myasthenia gravis patients, approximated the prevalence of
11 familial myasthenia gravis, compared the characteristics of familial disease with
12 sporadic disease, and assessed the co-morbidity of other autoimmune diseases among
13 patients and among their families.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 **METHODS**

32 **Patient ascertainment**

33 Phenotype information of 1,032 patients diagnosed with myasthenia gravis was
34 obtained from myasthenia gravis clinics at fourteen centers across North America
35 between January 2010 and January 2011.¹⁰ The numbers of myasthenia gravis patients
36 attending each of these clinics was not available for this study. Patients were diagnosed
37 by neurologists specializing in myasthenia gravis. Each myasthenia gravis diagnosis
38 was based on standard clinical criteria that included, but was not limited to, weakness,
39 fatigability, and electrophysiological, pharmacological (edrophonium test) and/or
40 serological abnormalities. Inclusion criteria for this study were as follows: confirmed
41 diagnosis of myasthenia gravis, non-Hispanic white ethnicity, and presence of anti-
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 AChR antibodies. Patients with anti-MuSK antibodies were excluded from the study.
4
5 The LRP4 antibody was discovered after the collection of the cohort was complete.
6
7 Thus, the LRP4 antibody status of the patients was not known. Family histories of
8
9 myasthenia gravis and other autoimmune diseases were systematically obtained for
10
11 each subject using a simple structured questionnaire (Table S1). A positive family
12
13 history was defined as having a first-degree (~50% of DNA in common), second-degree
14
15 (~25% of DNA in common), or third-degree (~12.5% of DNA in common) relative with
16
17 the disease. DNA samples were collected from each subject and used for genetic
18
19 analyses as previously reported.¹⁰ Patients with genetic forms of myasthenia gravis
20
21 were not explicitly excluded, though none of the cohort was known to have such a
22
23 mutation.
24
25
26
27
28
29
30

31 **Literature review methodology**

32
33 To find studies about the epidemiology of familial myasthenia gravis, the PubMed and
34
35 Medline databases were searched using permutations of search terms: 'epidemiology of
36
37 familial myasthenia gravis', 'epidemiology of myasthenia gravis', and 'heritability of
38
39 myasthenia gravis'. After reviewing thirty-one epidemiology studies between the years
40
41 of 1950 through 2018, only ten studies explicitly referenced the family history of
42
43 myasthenic patients. Five of those papers provided metrics about family members with
44
45 myasthenia gravis.¹²⁻¹⁶
46
47
48
49
50

51 **Patient and public involvement statement**

52
53 No patients or members of the public were actively involved with co-producing the
54
55
56
57
58
59
60

1
2
3 research presented in this article.
4
5
6
7

8 **Statement of ethics approval**

9
10 Written informed consent was obtained from all patients who participated in this study.

11
12 Institution review board (IRB) approval was obtained at all participating institutions.

13
14 Lead institutes for IRB = National Institutes of Health, protocol 03-AG-N329,

15
16 <https://clinicaltrials.gov/ct2/show/NCT02014246>
17
18
19
20

21 **Data availability**

22
23 The data, consisting of patient family history of myasthenia gravis and other
24
25 autoimmune diseases in addition to patient personal history of other autoimmune
26
27 diseases, are not publicly available because of patient privacy concerns but de-
28
29 identified participant data are available upon request by contacting the corresponding
30
31 author. In the interests of scientific rigor, the code used for analysis of the dataset is
32
33 available on GitHub: <https://github.com/neurogenetics/Familial-Myasthenia-Gravis>.
34
35
36
37
38
39

40 **RESULTS**

41 **North American cohort of myasthenia gravis patients**

42
43 Clinical data were collected from a total of 1,032 patients across fourteen centers in
44
45 North America and were analyzed in this study. All of the patients had positive anti-
46
47 AChR antibodies. The median age of symptom onset in this clinic-based cohort was 58
48
49 years of age (range = 4-91; median onset age for females = 46; median onset age for
50
51 males = 62). The female-to-male ratio was 1:1.27. Early-onset disease (< 40 years of
52
53
54
55
56
57
58
59
60

1
2
3 age) was observed among 248 (24.0%) of the cohort. Consistent with other reports,
4
5 nearly one third of the patients in our North American study cohort (305, 29.6%) had
6
7 undergone thymectomy.
8
9

10 Fifty-eight (5.6%) patients had a family history of myasthenia gravis. Sibling-
11
12 sibling (31.0%) and parent-child (32.8%) were the most common type of familial
13
14 relationship, followed by uncle/aunt-nephew/niece (13.8%), cousin-cousin (12.1%) and
15
16 grandparent-grandchild (5.2%) relationships. Of note, the indicated percentage of
17
18 parent-child cases might be inflated because neonatal myasthenia gravis cases (which
19
20 are not believed to be genetic) could not be discerned from non-neonatal cases. Age at
21
22 symptom onset was similar among patients with a family history compared to patients
23
24 without a family history (57.5 years of age, range = 8-80 years versus 58.5 years, range
25
26 = 4-91 years, p-value = 0.183, Wilcoxon rank sum test, figure 1, table 1).
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Comparison of familial and sporadic cases among a cohort of patients diagnosed with myasthenia gravis (n = 1,032)

	Familial	Sporadic	P-value
Number of myasthenia gravis cases (percent)	58 (5.6)	974 (94.4)	-
Median age of disease onset (years) (range)	57.5 (8-80)	58.5 (4-91)	0.183
Number of patients with early-onset disease (< 40 years) (percent)	15 (25.9)	233 (23.9)	0.86
Number of females (percent)	25 (43.1)	429 (44.0)	0.997

A personal history of an autoimmune disease other than myasthenia gravis was reported in 275 (26.6%) of study participants. A total of 293 (28.4%) subjects had a family history of an autoimmune disease. The prevalence of autoimmunity in the general population is ~3-9%, indicating that the rates observed among our myasthenia gravis subjects are significantly increased.¹⁷ A breakdown of the specific autoimmune diseases

1
2
3 for both personal history and family history of disease is shown in figure 2A and figure
4
5 2B.
6

7
8 The most common autoimmune diseases present concomitantly in myasthenia
9
10 gravis patients were thyroid disease (n = 118, 11.4%), hematological disease (n = 33,
11
12 3.2% consisting of autoimmune hemolytic anemia and autoimmune thrombocytopenic
13
14 purpura), and rheumatoid arthritis (n=28, 2.7%). This was similar to the rates previously
15
16 reported by Mao et al (figure 2C).¹⁸
17
18

19 The three most common autoimmune diseases present in the families of
20
21 myasthenia gravis patients were thyroid disease (n=98, 9.5%), rheumatoid arthritis
22
23 (n=68, 6.6%), and type 1 diabetes (n=36, 3.5%).
24
25
26
27

28 **Literature review**

29
30 Literature review concerning the epidemiology of familial myasthenia gravis identified
31
32 five studies that discussed the patient's family history of myasthenia gravis with sample
33
34 sizes that ranged from 264 to 6,638 (table 2).¹²⁻¹⁶ The frequency of familial myasthenia
35
36 gravis ranged from 0.2% to 7.2% across studies, the upper limit having been reported
37
38 based on a Finnish cohort.¹⁵ Among these, three studies reported that familial
39
40 myasthenia gravis cases had an earlier symptom onset age than the sporadic cases.^{12,}
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
14, 15 Only three studies reported on the patient history of other autoimmune diseases
and/or on the family history of other autoimmune diseases.^{12, 14, 15} Among these, thyroid
disease, rheumatoid arthritis, systemic lupus erythematosus, and Sjogren's syndrome
were the most common other autoimmune diseases reported in patients' personal
and/or family histories. ^{12, 14, 15}

Table 2. Studies reporting the rate of familial disease in myasthenia gravis.

Source	Origin	Sample size	Familial rate	Study type
12	Taiwan	6,638	0.2%	Population
13	Japan	3,141	0.7%	Population
14	Spain	462	3.5%	Clinic
15	Finland	264	7.2%	Population
16	United States	702	3.8%	Clinic

DISCUSSION

We found the prevalence of familial myasthenia gravis in our North American cohort to be 5.6%. This is comparable to the prevalence reported in other studies, where the frequency ranged from 0.2% to 7.2% of myasthenia gravis patients having a family history of myasthenia gravis depending on the cohort studied.¹²⁻¹⁶ Although the vast majority of myasthenia gravis cases are still non-familial, a prevalence of 5.6% represents a several hundred-fold increase for a disease with an overall prevalence of 1 in 5-10,000.⁵ The two studies of myasthenia gravis based on Asian cohorts reported substantially lower rates of familial disease compared to our North American cohort and

1
2
3 other European cohorts. For example, two studies of Taiwanese (n = 6,638) and
4
5 Japanese (n = 3,141) cohorts reported rates of familial myasthenia gravis at 0.2% and
6
7 0.7%, respectively.¹²⁻¹³ Three studies of Spanish, American, and Finnish cohorts
8
9 reported rates of 3.5%, 3.8%, and 7.2% (table 2).¹⁴⁻¹⁶ The familial rates reported in our
10
11 cohort of over 1,000 patients were, as expected, closer in value to the rates reported
12
13 among European and American cohorts. Overall, these data suggest that there is
14
15 population variation in the inheritance of myasthenia gravis that warrants further study
16
17 to identify the genetic contribution to disease risk.
18
19

20
21 A notable feature of our cohort is that males had a slightly higher prevalence of
22
23 familial myasthenia gravis compared to the females (1:1.32), suggesting that there
24
25 might be sex-specific differences in the occurrence of familial versus sporadic disease.
26
27 This observation may reflect the different age distribution of myasthenia gravis cases in
28
29 males versus females observed across all myasthenia gravis cases. The reason for this
30
31 is unclear, though we note that our previous genome-wide association study of
32
33 myasthenia gravis indicated that the genetic architecture was different among younger
34
35 and older age groups.¹⁰
36
37
38
39

40 Myasthenia gravis is an immunological disorder and, generally speaking,
41
42 autoimmune diseases are known to have heritable components.¹⁹ Likewise,
43
44 approximately one-third of our cohort had a personal history and/or a family history of
45
46 another autoimmune disease, which is much higher than the prevalence of 3-9%, which
47
48 has been historically reported in the general population.¹⁷ We found that 19% (11/58) of
49
50 the familial myasthenia gravis cases also had a personal history of autoimmune
51
52 diseases; this was more than the sporadic myasthenia gravis cases in which only 10%
53
54
55
56
57
58
59
60

1
2
3 (98/974) had a personal history of autoimmune diseases. Similar to previous reports, we
4
5 found thyroid disease, rheumatoid arthritis, systemic lupus erythematosus, and type 1
6
7 diabetes to be the most commonly identified comorbidities (figure 2C).^{18, 19} Interestingly,
8
9 the frequency of thyroid disease in this cohort (11.4%) is similar to the frequency range
10
11 of thyroid disease reported in a study by Kiessling et al.²⁰ The increased prevalence of
12
13 familial myasthenia gravis and increased prevalence of other autoimmune disorders
14
15 both suggest that these autoimmune diseases may share a common predisposition that
16
17 may be genetic in origin. Future studies focusing on specific genes and genomic
18
19 variants encountered in patients with familial myasthenia gravis offer the promise to
20
21 more precisely identify any genetic contributions to the disease.
22
23
24
25

26 While our study has some notable strengths, it also has an inherent limitation
27
28 related to its reliance on self-reported family histories, which could have over- or
29
30 underestimated the prevalence of the diseases studied. For example, it is plausible that
31
32 a patient could self-report as not having a family history of myasthenia gravis because
33
34 the family member was never clinically diagnosed with the disease or did not live long
35
36 enough for the disease to manifest. Similarly, other studies have found an
37
38 overestimation of some autoimmune diseases, especially thyroid disease and
39
40 rheumatoid arthritis, related to self-reporting.²¹
41
42
43
44

45 Our analyses provide evidence of a genetic contribution to myasthenia gravis
46
47 based on the higher than expected rate of familial disease observed among our North
48
49 American patient cohort, as well as the co-occurrence of autoimmune diseases known
50
51 to have a genetic basis among this population. More work needs to be done to further
52
53 elucidate the genetic etiology of this archetypal autoimmune disease.
54
55
56
57
58
59
60

ACKNOWLEDGEMENTS

This work was supported in part by the Intramural Research Programs of the National Institutes of Health National Institute on Aging (Z01-AG000949-02). The work was also supported by the Myasthenia Gravis Foundation (Drs Drachman and Traynor), a generous bequest by Geraldine Weinrib, and a gift from Philip Swift. Support was provided by Mr. and Mrs. Don Brandon and the Department of Neurology, University of Kansas Medical Center. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. We thank the patients and research participants who contributed samples for this study.

Competing interests

Mr. Green none declared.

Dr. Barohn served as a consultant for NuFactor and Momenta Pharmaceutical and receives research support from PTC Therapeutics, Ra Pharma, Orphazyme, Sanofi Genzyme, FDA OOPD, NIH, and PCORI.

Dr. Bartoccion none declared.

Dr. Benetar reports grant support from Muscular Dystrophy Association, ALS Association, ALS Recovery Fund, Kimmelman Estate, Target ALS, Eli Lilly & Company, and the National Institutes of Health (NIH) during the conduct of the study. He also

1
2
3 reports grant support from FDA, CDC, and DOD; research support from Alexion
4
5 Pharmaceuticals, UCB, Cytokinetics, Neuraltus, Biogen and Orphazyme A/S; and
6
7 personal fees from NMD Pharma, Ra Pharmaceuticals, Mitsubishi-Tanabe, Avexis,
8
9 UCB and Denali outside the submitted work.
10

11
12 Mr. Blackmore none declared
13

14
15 Dr. Chaudhry served as a consultant for review and expert testimony for the
16
17 Department of Health and Human Services and the Department of Justice under the
18
19 Vaccine Injury and Compensation Program. Dr. Chaudhry has received royalty for total
20
21 neuropathy score (TNS) patented (through Johns Hopkins University) for license of TNS
22
23 use from AstraZeneca, Genentech, Seattle Genetics, Calithera Biosciences, Inc,
24
25 Merrimack Pharmaceuticals, Inc., Levicept, and Acetylon Pharmaceuticals, Inc.
26
27

28
29 Dr. Chopra none declared.
30

31
32 Dr. Corse none declared.
33

34
35 Dr. Dimachkie serves or recently served as a consultant for ArgenX, Catalyst, CSL-
36
37 Behring, Kezar, Momenta, NuFactor, RMS Medical, Sanofi Genzyme, Shire Takeda,
38
39 and Spark Therapeutics. Dr. Dimachkie received grants from Alexion, Alnylam
40
41 Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, CSL-Behring,
42
43 FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Mitsubishi Tanabe Pharma, MDA,
44
45 NIH, Novartis, Sanofi Genzyme, Octapharma, Orphazyme, Sarepta Therapeutics, Shire
46
47 Takeda, Spark, UCB Biopharma, Viomed & TMA.
48

49
50 Dr. Evoli was a member of the advisory board for Alexion, a scientific award jury
51
52 member for Grifols and safety data monitor for UCB.
53

54
55 Dr. Florence none declared.
56
57
58
59
60

1
2
3 Dr. Freimer has received honoraria for serving on advisory boards for ARGNX pharma,
4 Alexion. Dr. Freimer also has research support from Catalyyst, Ra pharma, Amicus,
5 Orphazyme, Alexion, Momenta and Alnylum.
6
7

8
9
10 Dr. Howard reports research support and grants from Alexion Pharmaceuticals, argenx
11 BVBA, Centers for Disease Control and Prevention, Muscular Dystrophy Association,
12 NIH (including the National Institute of Neurologic Disorders and Stroke and the
13 National Institute of Arthritis and Musculoskeletal and Skin Disease), PCORI (Patient-
14 Centered Outcomes Research Institute), and Ra Pharmaceuticals; and nonfinancial
15 support from Alexion Pharmaceuticals, argenx BVBA, Ra Pharmaceuticals, and
16 Toleranzia.
17
18

19 Dr. Jiwa none declared.
20

21 Dr. Kaminski is funded by the Muscular Dystrophy Association (508240) and by NIH
22 grant U54NS115054; is a consultant for Alnylam Pharmaceuticals, Ra Pharmaceuticals,
23 and UCB Pharmaceuticals; and is CEO of ARC Biotechnology, LLC, which receives
24 support from the NIH (R41NS110331). He serves on the Editorial Board of Experimental
25 Neurology.
26
27

28 Dr. Kissel none declared.
29

30 Ms. Koopman none declared.
31

32 Ms. Lipscomb none declared.
33

34 Dr. Maestri none declared.
35

36 Dr. Marino none declared.
37

38 Dr. Massey none declared
39

40 Dr. McVey none declared.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Dr. Mezei has received honoraria as a speaker and/or moderator from Alnylam, Akcea,
4
5 Pfizer and CSL Behring. She has served on Advisory Boards for Pfizer, Alnylam and
6
7 Akcea. She serves as an investigator for clinical trials with Alnylam and Biogen.
8
9

10 Dr. Muppidi has served on advisory board meetings for Alexion and argenx.
11

12 Dr. Nicolle none declared.
13

14 Dr. Oger none declared.
15

16 Dr. Pascuzzi none declared.
17

18
19 Dr. Pasnoor served on advisory board for CSL Behring, Alexion pharmaceuticals,
20
21 Argenx Pharmaceuticals and has been consultant for Momenta Pharmaceuticals.
22
23

24 Dr. Pestronk none declared.
25

26 Dr. Provenzano none declared.
27

28 Dr. Ricciardi none declared.
29

30
31 Dr. Richman receives research funding from a Sponsored Research Agreement from
32
33 Cabaletta Bioscience.
34

35 Dr. Rowin none declared.
36

37 Dr. Sanders none declared.
38

39 Dr. Siddiqi none declared.
40

41 Ms. Soloway none declared
42
43

44 Dr. Wolfe none declared.
45

46 Dr. Wulf none declared.
47

48 Dr. Drachman none declared.
49

50
51 Dr. Traynor holds an American and European Union patent on the clinical testing and
52
53 therapeutic intervention for the hexanucleotide repeat expansion of C9orf72. Has
54
55

1
2
3 received research grants from The Myasthenia Gravis Foundation, the Robert Packard
4 Center for ALS Research, the ALS Association (ALSA), the Italian Football Federation
5 (FIGC), the Center for Disease Control and Prevention (CDC), the Muscular Dystrophy
6 Association (MDA), Merck Inc., and Microsoft Research. Dr. Traynor receives funding
7 through the Intramural Research Program at the National Institutes of Health.
8
9

14 **Funding**

15
16 Study funding by the National Institutes of Health Intramural Research Program. The
17 work was also supported by the Myasthenia Gravis Foundation (Drs Drachman and
18 Traynor), a generous bequest by Geraldine Weinrib, and a gift from Philip Swift. Support
19 was provided by Mr. and Mrs. Don Brandon and the Department of Neurology,
20 University of Kansas Medical Center.
21
22
23
24
25
26
27
28
29
30

31 **References**

- 32
33
34 1. Fambrough DM, Drachman DB, Satyamurti S. Neuromuscular
35 junction in myasthenia gravis: decreased acetylcholine receptors. *Science* 1973;
36 182:293-295.
37
38
39
40 2. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-
41 antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis
42 without acetylcholine receptor antibodies. *Nat Med* 2001;7:365-368.
43
44
45
46 3. Gasperi C, Melms A, Schoser B, et al. Anti-agrin autoantibodies in myasthenia
47 gravis. *Neurology* 2014;82:1976-1983.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 4. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density
4 lipoprotein receptor-related protein 4 in myasthenia gravis. *Ann Neurol* 2011;69:418-
5
6 422.
7
- 8
9
10 5. Jayam Trough A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia
11
12 gravis: a review. *Autoimmune Dis* 2012;2012:874680.
13
- 14 6. McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia gravis: a
15
16 systematic literature review. *Neuroepidemiology* 2010;34:171-183.
17
- 18 7. Yu YL, Hawkins BR, Ip MS, Wong V, Woo E. Myasthenia gravis in Hong Kong
19
20 Chinese. 1. Epidemiology and adult disease. *Acta Neurol Scand* 1992;86:113-119.
21
- 22 8. MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and
23
24 lifetime prevalence of neurological disorders in a prospective community-based study in
25
26 the UK. *Brain* 2000;123 (Pt 4):665-676.
27
- 28 9. Spillane J, Higham E, Kullmann DM. Myasthenia gravis. *BMJ* 2012;345:e8497.
29
- 30 10. Renton AE, Pliner HA, Provenzano C, et al. A genome-wide association study of
31
32 myasthenia gravis. *JAMA Neurol* 2015;72:396-404.
33
- 34 11. Giraud M, Vandiedonck C, Garchon HJ. Genetic factors in autoimmune
35
36 myasthenia gravis. *Ann N Y Acad Sci* 2008;1132:180-192.
37
- 38 12. Liu FC, Kuo CF, See LC, Tsai HI, Yu HP. Familial aggregation of myasthenia
39
40 gravis in affected families: a population-based study. *Clin Epidemiol* 2017;9:527-535.
41
- 42 13. Murai H, Yamashita N, Watanabe M, et al. Characteristics of myasthenia gravis
43
44 according to onset-age: Japanese nationwide survey. *J Neurol Sci* 2011;305:97-102.
45
- 46 14. Salvado M, Canela M, Ponseti JM, et al. Study of the prevalence of familial
47
48 autoimmune myasthenia gravis in a Spanish cohort. *J Neurol Sci* 2016;360:110-114.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 15. Pirskanen R. Genetic aspects in myasthenia gravis. A family study of 264 Finnish
4 patients. *Acta Neurol Scand* 1977;56:365-388.
5
6
- 7 16. Namba T, Brunner NG, Brown SB, Murguruma M, Grob D. Familial myasthenia
8 gravis. Report of 27 patients in 12 families and review of 164 patients in 73 families.
9
10 *Arch Neurol* 1971;25:49-60.
11
12
- 13 17. Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of
14 autoimmune diseases: improved prevalence estimates and understanding of clustering
15 of diseases. *J Autoimmun* 2009;33:197-207.
16
17
- 18 18. Mao ZF, Yang LX, Mo XA, et al. Frequency of autoimmune diseases in
19 myasthenia gravis: a systematic review. *Int J Neurosci* 2011;121:121-129.
20
21
- 22 19. Ceccarelli F, Agmon-Levin N, Perricone C. Genetic Factors of Autoimmune
23 Diseases. *J Immunol Res* 2016;2016:1-2.
24
25
- 26 20. Kiessling WR, Finke R, Kotulla P, Schleusener H. Circulating TSH-binding
27 inhibiting immunoglobulins in myasthenia gravis. *Acta Endocrinol (Copenh)*
28
29 1982;101:41-46.
30
31
- 32 21. O'Rourke JA, Ravichandran C, Howe YJ, Mullett JE, Keary CJ, Golas SB,
33 Hureau AR, McCormick M, Chung J, Rose NR, McDougale CJ. Accuracy of self-reported
34 history of autoimmune disease: A pilot study. *PLoS ONE* 2019;14(5): e0216526
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Figures

Figure 1.

Symptom-onset age distribution of sporadic and familial cases. The density represents the relative probability of myasthenia gravis at each age point.


Figure 2.

Autoimmune diseases in a cohort of 1,032 patients with myasthenia gravis. (A) Occurrence of autoimmune diseases among patients with myasthenia (n = 275). (B) Occurrence of autoimmune diseases among familial relatives of patients with myasthenia gravis (n = 293). (C) Comparisons of autoimmune diseases among patients with myasthenia gravis and among relatives. Size of circles represent the percentage previously reported by Mao et al.¹⁸




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

A. Personal history of autoimmune diseases



B. Family history of autoimmune diseases



C. Relationships between personal and family histories of autoimmune diseases




Table S1. Questionnaire used to collect demographic and clinical information from patients diagnosed with myasthenia gravis

Patient Information	
Patient identification number:	String (e.g., JHU1, JHU2)
Institution:	String (e.g., Johns Hopkins, UWO)
Date:	Date
Verified as Caucasian?	Yes/No
AChR titer - Initial or 1st known:	Numeric
Age at symptom onset (years):	Numeric
Gender:	Male/Female
Worst status	
Diplopia or ptosis only?	Yes/No
Mild limb weakness?	Yes/No
Dysphagia dyspnea?	Yes/No
Severe limb weakness?	Yes/No
Hospitalized?	Yes/No
Ventilated?	Yes/No
Feeding tube?	Yes/No
Treatment	
Mestinon?	Yes/No
Benefit: Mestinon:	Ordinal scale [0,1,2]
Prednisone?	Yes/No
Benefit: Prednisone:	Ordinal scale [0,1,2]
CellCept?	Yes/No
Benefit: CellCept?	Ordinal scale [0,1,2]
Cyclosporine?	Yes/No
Benefit: Cyclosporine:	Ordinal scale [0,1,2]
Tacrolimus?	Yes/No
Benefit: Tacrolimus:	Ordinal scale [0,1,2]
Intravenous immunoglobulin?	Yes/No
Benefit: Intravenous immunoglobulin:	Ordinal scale [0,1,2]
Plasmapheresis?	Yes/No
Benefit: Plasmapheresis:	Ordinal scale [0,1,2]
Imuran/Azathioprine?	Yes/No
Benefit: Imuran/Azathioprine:	Ordinal scale [0,1,2]
Other treatment?	Yes/No
Name of other 1:	String (e.g., Mytelase)
Benefit: other 1:	Ordinal scale [0,1,2]
Name of other 2:	String (e.g., Mytelase)
Benefit: other 2:	Ordinal scale [0,1,2]

Best Status	
Back to normal without medication?	Yes/No
Back to normal with medication?	Yes/No
Diplopia or ptosis only?	Yes/No
Mild limb weakness?	Yes/No
Dysphagia/dyspnea?	Yes/No
Severe limb weakness?	Yes/No
Hospitalized?	Yes/No
Ventilated?	Yes/No
Feeding tube:	Yes/No
Other Autoimmune Diseases	
Other autoimmune disease?	Yes/No
Thyroiditis?	Yes/No
Lupus?	Yes/No
Rheumatoid arthritis?	Yes/No
Psoriasis?	Yes/No
Blood disease?	Yes/No
Other Autoimmune Disease?	Yes/No
Other Autoimmune Disease (Name1):	String (e.g., vitiligo, celiac disease)
Other Autoimmune Disease (Name2):	String (e.g., vitiligo, celiac disease)
Other Autoimmune Disease (Name3):	String (e.g., vitiligo, celiac disease)
Family history of myasthenia gravis	
Family history of myasthenia gravis?	Yes/No
Myasthenia gravis (Relationship):	String (e.g., mother, sister)
Family history of other Autoimmune Disease	
Family history of other Autoimmune Disease?	Yes/No
Autoimmune Disease (Relationship):	String (e.g., mother, sister)
Autoimmune Disease (Disease):	String (e.g., polymyalgia, vitiligo)
Family history of other Autoimmune Disease 2nd Member?	Yes/No
Autoimmune Disease (Relationship) 2nd Member:	String (e.g., mother, sister)
Autoimmune Disease (Disease) 2nd Member:	String (e.g., polymyalgia, vitiligo)
Family history of other Autoimmune Disease 3rd Member?	Yes/No
Autoimmune Disease (Relationship) 3rd Member:	String (e.g., mother, sister)
Autoimmune Disease (Disease) 3rd Member:	String (e.g., polymyalgia, vitiligo)
Other relative in study?	Yes/No
Other relative in study id	String (e.g., JHU1, JHU2)
Thymectomy?	Yes/No
Thymoma?	Yes/No
Histology of thymus if known?	String (e.g., Follicular Hyperplasia)

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cohort studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	7-8
Introduction			10-11
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	10-11
Objectives	3	State specific objectives, including any prespecified hypotheses	11
Methods			11-13
Study design	4	Present key elements of study design early in the paper	11
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	11-13
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	11
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	11-13
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	11-13
Bias	9	Describe any efforts to address potential sources of bias	11-13
Study size	10	Explain how the study size was arrived at	11-13
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	11-13
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	14-15
		(b) Describe any methods used to examine subgroups and interactions	14-15
		(c) Explain how missing data were addressed	14-15
		(d) If applicable, explain how loss to follow-up was addressed	14-15
		(e) Describe any sensitivity analyses	NA
Results			13-15

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7,11,14
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	13
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Report numbers of outcome events or summary measures over time	13-15
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13-15
		(b) Report category boundaries when continuous variables were categorized	13-15
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	13-15
Discussion			16-18
Key results	18	Summarise key results with reference to study objectives	16-18
Limitations			17-18
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17-18
Generalisability	21	Discuss the generalisability (external validity) of the study results	17-18
Other information			NA
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	23

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037909.R2
Article Type:	Original research
Date Submitted by the Author:	08-Jul-2020
Complete List of Authors:	<p>Green, Joshua; National Institute on Aging Intramural Research Program, Neuromuscular Diseases Research Unit, Laboratory of Neurogenetics</p> <p>Barohn, Richard; University of Kansas Medical Center, Department of Neurology</p> <p>Bartoccion, Emanuela; Catholic University, Fondazione Policlinico Universitario "A. Gemelli" - I.R.C.C.S, Institute of General Pathology</p> <p>Benetar, Michael; University of Miami, Department of Neurology</p> <p>Blackmore, Derrick; University of Alberta Hospital, Department of Medicine</p> <p>Chaudhry, Vinay; Johns Hopkins School of Medicine, Department of Neurology</p> <p>Chopra, Manisha ; University of North Carolina at Chapel Hill, Department of Neurology</p> <p>Corse, Andrea; Johns Hopkins School of Medicine, Department of Neurology</p> <p>Dimachkie, Mazen M.; University of Kansas Medical Center, Department of Neurology</p> <p>Evoli, Amelia ; Policlinico A. Gemelli IRCSS, Università Cattolica del S. Cuore, Istituto di Neurologia</p> <p>Florence , Julaine ; Washington University School of Medicine in Saint Louis, Department of Neurology</p> <p>Freimer , Miriam ; Ohio State University Medical Center, Department of Neurology</p> <p>Howard, James ; University of North Carolina at Chapel Hill, Department of Neurology</p> <p>Jiwa, Theresa; University of British Columbia, Division of Neurology</p> <p>Kaminski , Henry ; George Washington University</p> <p>Kissel, JT; Ohio State University Medical Center, Department of Neurology</p> <p>Koopman, Wilma; London Health Sciences Centre, Department of Clinical Neurosciences,</p> <p>Lipscomb, Bernadette ; Duke University Medical Center, Department of Neurology</p> <p>Maestri , Michelangelo ; University of Pisa, Department of Neuroscience</p> <p>Marino, Mariapaola ; Catholic University, Fondazione Policlinico Universitario "A. Gemelli" - I.R.C.C.S., Institute of General Pathology</p> <p>Massey, Janice; Duke University Medical Center, Department of Neurology</p>

	<p>McVey , April ; University of Kansas Medical Center, Department of Neurology</p> <p>Mezei , Michelle ; The University of British Columbia, Division of Neurology</p> <p>Muppidi , Srikanth ; Stanford University, Department of Neurology and Neurosciences</p> <p>Nicolle, Michael ; London Health Sciences Centre, Division of Neurology</p> <p>Oger, Joel; The University of British Columbia, Division of Neurology</p> <p>Pascuzzi , Robert ; Indiana University Purdue University at Indianapolis, Department of Neurology</p> <p>Pasnoor , Mamatha ; University of Kansas Medical Center, Department of Neurology</p> <p>Pestronk , Alan ; Washington University School of Medicine in Saint Louis, Department of Neurology</p> <p>Provenzano , Carlo ; Catholic University, Fondazione Policlinico Universitario "A. Gemelli" - I.R.C.C.S, Institute of General Pathology</p> <p>Ricciardi , Roberta ; University of Pisa, Department of Neuroscience</p> <p>Richman, DP; Center for Neuroscience, University of California, Neurology</p> <p>Rowin, Julie ; APAC Centers for Pain Management Wellness and Integrative Neurology</p> <p>Sanders, Donald ; Duke University Medical Center, Department of Neurology</p> <p>Siddiqi , Zaeem ; University of Alberta Hospital, Department of Medicine</p> <p>Soloway, Aimee ; University of Alberta Hospital, Department of Medicine</p> <p>Wolfe, Gil ; State University of New York at Buffalo, Department of Neurology</p> <p>Wulf, Charlie; Washington University School of Medicine in Saint Louis, Department of Neurology</p> <p>Drachman, Daniel ; Johns Hopkins School of Medicine</p> <p>Traynor, Bryan ; National Institute on Aging Intramural Research Program, Neuromuscular Diseases Research Unit, Laboratory of Neurogenetics</p>
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Neurology
Keywords:	EPIDEMIOLOGY, Neuromuscular disease < NEUROLOGY, GENETICS, Neurology < INTERNAL MEDICINE, Neurogenetics < NEUROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 Epidemiological evidence for a hereditary contribution to myasthenia gravis: a
4 retrospective cohort study of patients from North America
5
6
7
8
9

10 Joshua D. Green, BS; Richard J. Barohn, MD; Emanuela Bartoccion, PhD; Michael
11 Benetar, MD, PhD; Derrick Blackmore, BSc; Vinay Chaudhry, MD; Manisha Chopra,
12 MD; Andrea Corse, MD; Mazen M. Dimachkie, MD; Amelia Evoli, MD; Julaine Florence,
13 PT, MHS, DPT; Miriam Freimer, MD; James F. Howard Jr, MD; Theresa Jiwa; Henry J.
14 Kaminski, MD; John Kissel, MD; Wilma J. Koopman, RN; Bernadette Lipscomb, RN;
15 Michelangelo Maestri, MD; Mariapaola Marino, MD; Janice M. Massey, MD; April McVey,
16 MD; Michelle M. Mezei, MD; Srikanth Muppidi, MD; Michael W. Nicolle, MD; Joel Oger,
17 MD; Robert M. Pascuzzi; Mamatha Pasnoor, MD; Alan Pestronk, MD; Carlo
18 Provenzano, MD, PhD; Roberta Ricciardi, MD; David P. Richman, MD; Julie Rowin,
19 MD; Donald B. Sanders, MD; Zaeem Siddiqi, MD; Aimee Soloway, RN; Gil I. Wolfe, MD;
20 Charlie Wulf, BS; Daniel B. Drachman, MD*; and Bryan J. Traynor, MD, PhD*
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 * These authors contributed equally to the manuscript.
36
37
38
39

40 **Author Contributions:** The study concept and design were proposed by DBD and BJT.
41 The acquisition, analysis, and/or interpretation of data provided done by all authors. The
42 manuscript was drafted by JDG and BJT. Critical revisions, intellectual contributions,
43 and final approval were provided by DBD, RJB, EB, MB, DB, VC, MC, AC, MD, AE, JF,
44 MF, JH, TJ, HJK, JK, WJK, BL, MM, MM, JMM, AM, MM, SM, MN, JO, RMP, MP, AP,
45 CP, RR, DR, JR, DBS, ZS, AS, GIW, and CW. The statistical analysis for this study was
46 provided by JDG.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Affiliations

Joshua D. Green, Neuromuscular Diseases Research Unit, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Porter Neuroscience Research Center, Bethesda, Maryland

Richard J. Barohn, Department of Neurology, University of Kansas Medical Center, Kansas City

Emanuela Bartoccion, Institute of General Pathology, Catholic University, Fondazione Policlinico Universitario "A. Gemelli" - I.R.C.C.S, Rome, Italy.

Michael Benetar, Department of Neurology, University of Miami, Miami, Florida

Derrick Blackmore, Department of Medicine, University of Alberta Hospital, Edmonton, Alberta, Canada

Vinay Chaudhry, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland

Manisha Chopra, Department of Neurology, University of North Carolina, Chapel Hill

Andrea Corse, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland

Mazen M. Dimachkie, Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas

Amelia Evoli, Istituto di Neurologia, Policlinico A. Gemelli IRCSS, Università Cattolica del S. Cuore, Roma, Italy

Julaine Florence, Department of Neurology, Washington University School of Medicine,

1
2
3 St Louis, Missouri

4
5 Miriam Freimer, Department of Neurology, Ohio State University Medical Center,
6
7
8 Columbus

9
10 James F. Howard Jr, Department of Neurology, University of North Carolina, Chapel Hill

11
12 Theresa Jiwa, Division of Neurology, University of British Columbia, Vancouver, British
13
14 Columbia, Canada

15
16 Henry J. Kaminski, Department of Neurology, George Washington University,
17
18 Washington, DC

19
20 John Kissel, Department of Neurology, Ohio State University Medical Center, Columbus

21
22 Wilma J. Koopman, Department of Clinical Neurosciences, London Health Sciences
23
24 Centre, London, Ontario, Canada

25
26 Bernadette Lipscomb, Department of Neurology, Duke University Medical Center,
27
28 Durham, North Carolina

29
30 Michelangelo Maestri, Department of Neuroscience, Cisanello Hospital, University of
31
32 Pisa, Pisa, Italy

33
34 Mariapaola Marino, Institute of General Pathology, Catholic University, Fondazione
35
36 Policlinico Universitario "A. Gemelli" - I.R.C.C.S, Rome, Italy.

37
38 Janice M. Massey, Department of Neurology, Duke University Medical Center, Durham,
39
40 North Carolina

41
42 April McVey, Department of Neurology, University of Kansas Medical Center, Kansas
43
44 City

45
46 Michelle M. Mezei, Division of Neurology, University of British Columbia, Vancouver,
47
48 British Columbia, Canada

1
2
3 Srikanth Muppidi, Clinical Associate Professor, Dept of Neurology and Neurosciences.
4
5 Stanford University
6

7 Michael W. Nicolle, Department of Clinical Neurosciences, London Health Sciences
8
9 Centre, London, Ontario, Canada
10

11
12 Joel Oger, Division of Neurology, University of British Columbia, Vancouver, British
13
14 Columbia, Canada
15

16
17 Robert M. Pascuzzi, Department of Neurology, Indiana University–Purdue University,
18
19 Indianapolis
20

21
22 Mamatha Pasnoor, Department of Neurology, University of Kansas Medical Center,
23
24 Kansas City
25

26
27 Alan Pestronk, Department of Neurology, Washington University School of Medicine, St
28
29 Louis, Missouri
30

31
32 Carlo Provenzano, Institute of General Pathology, Catholic University, Fondazione
33
34 Policlinico Universitario "A. Gemelli" - I.R.C.C.S, Rome, Italy.
35

36
37 Roberta Ricciardi, Department of Neuroscience, Cisanello Hospital, University of Pisa,
38
39 Pisa, Italy
40

41
42 David P. Richman, Department of Neurology, University of California, Davis
43

44
45 Julie Rowin, APAC Centers for Pain Management Wellness and Integrative Neurology
46
47 Westchester, Illinois
48

49
50 Donald B. Sanders, Department of Neurology, Duke University Medical Center,
51
52 Durham, North Carolina
53

54
55 Zaeem Siddiqi, Department of Medicine, University of Alberta Hospital, Edmonton,
56
57 Alberta, Canada
58
59

1
2
3 Aimee Soloway, Department of Medicine, University of Alberta Hospital, Edmonton,
4
5 Alberta, Canada
6

7
8 Gil I. Wolfe, Department of Neurology, University at Buffalo Jacobs SMBS, State
9
10 University of New York, Buffalo
11

12
13 Charlie Wulf, Department of Neurology, Washington University School of Medicine, St
14
15 Louis, Missouri
16

17
18 Daniel Drachman, Department of Neurology, Johns Hopkins School of Medicine,
19
20 Baltimore, Maryland
21

22
23 Bryan J. Traynor, Neuromuscular Diseases Research Unit, Laboratory of
24
25 Neurogenetics, National Institute on Aging, National Institutes of Health, Porter
26
27 Neuroscience Research Center, Bethesda, Maryland
28
29

30
31 **Corresponding Author:**
32

33 Bryan J. Traynor MD PhD,
34

35 35 Convent Drive, Room 1A-213, Bethesda, MD 20892-3707.
36

37 *Phone:* 301-451-7606.
38

39
40 traynorb@mail.nih.gov
41
42
43

44
45 **Author Contact Information:**
46

47 Joshua D. Green josh.green@nih.gov
48

49 Richard J. Barohn rbarohn@kumc.edu
50

51 Emanuela Bartoccion ebartoc@gmail.com
52

53
54 Michael Benetar MBenatar@med.miami.edu
55
56
57
58
59
60

1
2
3 Derrick Blackmore dblackmo@ualberta.ca
4
5 Vinay Chaudhry vchaudh@jhmi.edu
6
7 Manisha Chopra chopram@neurology.unc.edu
8
9
10 Andrea Corse acorse@jhmi.edu
11
12 Mazen M. Dimachkie mdimachkie@kumc.edu
13
14 Amelia Evoli amelia.evoli@unicatt.it
15
16
17 Julaine Florence florencej@neuro.wustl.edu
18
19 Miriam Freimer miriam.freimer@osumc.edu
20
21 James F. Howard Jr howardj@neurology.unc.edu
22
23
24 Theresa Jiwa theresajiwa@shaw.ca
25
26 Henry J. Kaminski henrykaminski@gmail.com
27
28 John Kissel John.Kissel@osumc.edu
29
30
31 Wilma J. Koopman wkoopman@uwo.ca
32
33 Bernadette Lipscomb btlipscomb@gmail.com
34
35 Michelangelo Maestri michelangelo.mvg@tin.it
36
37 Mariapaola Marino mariapaola.marino@unicatt.it
38
39
40 Janice M. Massey masse005@mc.duke.edu
41
42 April McVey aprillynnmcvey@gmail.com
43
44 Michelle M. Mezei mezei@mail.ubc.ca
45
46 Srikanth Muppidi muppidis@stanford.edu
47
48
49 Michael W. Nicolle mnicolle@uwo.ca
50
51 Joel Oger joel.oger@ubc.ca
52
53 Robert M. Pascuzzi rpascuzz@iupui.edu
54
55
56
57
58
59
60

1
2
3 Mamatha Pasnoor mpasnoor@kumc.edu
4

5 Alan Pestronk pestronka@neuro.wustl.edu
6

7 Carlo Provenzano carlo.provenzano@unicatt.it
8

9
10 Roberta Ricciardi r.ricciardi@ao-pisa.toscana.it
11

12 David P. Richman dprichman@ucdavis.edu
13

14 Julie Rowin jrowin@apacgroupe.com
15

16 Donald B. Sanders sande007@mc.duke.edu
17

18 Zaeem Siddiqi zsiddiqi@ualberta.ca
19

20 Aimee Soloway Aimee.Soloway@albertahealthservices.ca
21

22 Gil I. Wolfe gilwolfe@buffalo.edu
23

24 Charlie Wulf wulfc@neuro.wustl.edu
25

26 Daniel Drachman dandrac@aol.com
27

28 Bryan J. Traynor traynorb@mail.nih.gov
29
30
31
32
33
34

35 Submission Type: **Original Research**
36

37 Title Character count: **136**
38

39 Number of Tables: **3**
40

41 Number of Figures: **2**
42

43 Number of References: **23**
44

45 Word count of Abstract: **169**
46

47 Word count of Paper: **2097**
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Statistical analysis:** conducted by Joshua Green, BS, and Dr. Bryan Traynor, MD,
4
5 PhD, National Institutes of Health.
6
7
8
9
10
11
12
13
14
15
16

17 **ABSTRACT**

18
19 **Objectives** To approximate the rate of familial myasthenia gravis and the coexistence
20
21 of other autoimmune disorders in the patients and their families.
22

23
24 **Design** Retrospective cohort study
25

26 **Setting** Clinics across North America
27

28 **Participants** The study included 1,032 patients diagnosed with acetylcholine receptor
29
30 antibody (AChR)-positive myasthenia gravis
31

32
33 **Methods** Phenotype information of 1,032 patients diagnosed with acetylcholine
34
35 receptor antibody (AChR)-positive myasthenia gravis was obtained from clinics at
36
37 fourteen centers across North America between January 2010 and January 2011. A
38
39 critical review of the epidemiological literature on the familial rate of myasthenia gravis
40
41 was also performed.
42
43

44 **Results** Among 1,032 patients, 58 (5.6%) reported a family history of myasthenia
45
46 gravis. A history of autoimmune diseases was present in 26.6% of patients and in
47
48 28.4% of their family members.
49

50
51 **Discussion** The familial rate of myasthenia gravis was higher than would be expected
52
53 for a sporadic disease. Furthermore, a high proportion of patients had a personal or
54
55
56
57
58
59
60

1
2
3 family history of autoimmune disease. Taken together, these findings suggest a genetic
4
5 contribution to the pathogenesis of myasthenia gravis.
6
7
8
9
10

11 12 **ARTICLE SUMMARY**

13 14 **Strengths and limitations of this study**

- 15
16
17 • A strength of this study is that it analyzes a large cohort of myasthenia gravis
18 patients with complete data on each patient, allowing multiple clinical correlations
19 to be made.
20
21
- 22
23
24 • A strength of this study is that standardized criteria were used to diagnose
25 patients with myasthenia gravis, including establishing the specific subtype of the
26 disease for each patient.
27
28
- 29
30
31 • A strength of this study is that the cohort of myasthenia gravis patients was
32 sufficiently large to allow the generation of evidence confirming a genetic
33 contribution to the disease.
34
35
- 36
37
38 • A limitation of this study is the reliance on self-reported family history status for
39 both myasthenia gravis and other autoimmune diseases by the patients.
40
41
- 42
43 • A limitation of this study is its retrospective design, which precludes ascertaining
44 additional information from individual patients.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Myasthenia gravis is a rare autoimmune disease that is characterized by antibody-mediated interference with neuromuscular transmission at the neuromuscular junction. Originally, the role for an autoimmune attack against the acetylcholine receptor (AChR) on the postsynaptic side of the neuromuscular junction was recognized.¹ However, over the past decade, additional autoimmune targets have been identified: muscle-specific tyrosine kinase (MuSK), agrin, and lipoprotein receptor-related protein 4 (LRP4).²⁻⁴ All of these proteins play essential roles in maintaining the structure and function of the neuromuscular junction.

Myasthenia gravis manifests clinically with muscle weakness and fatigability. Symptoms of ocular muscle weakness are observed early in 85% of myasthenic patients.⁵ These symptoms include diplopia and/or ptosis. Weakness of the bulbar musculature is observed in 60% of myasthenic patients, with symptoms including dysarthria and/or dysphagia.⁵

A recent literature review of thirty-one epidemiological studies suggests that the annual incidence of myasthenia gravis may range between 3 and 30 cases per million people.⁶ A common theme among myasthenia gravis epidemiological studies is that there is a significant degree of variability between cohorts. For example, a study of a Hong Kong Chinese cohort reported an incidence of 4 per million people per year, whereas a study of an English cohort reported an incidence of 30 per million people per year.^{7, 8} This substantial degree of variability may be the result of inconsistent diagnostic criteria, varying case ascertainment, lack of physician awareness concerning myasthenia gravis, or it may reflect different occurrence across populations.

1
2
3 Historically, adult-onset myasthenia gravis has been regarded as a sporadic
4 disease with only a minimal genetic component.⁹ However, genome-wide association
5 studies, fine-mapping studies, and epidemiological studies of myasthenia gravis
6 suggest a genetic contribution to the disease.^{10, 11} In fact, studies have described
7 myasthenic patients with a family history of myasthenia gravis and/or a family history of
8 autoimmune diseases.¹²⁻¹⁶ In this study, we performed a literature search of the familial
9 rate reported by myasthenia gravis epidemiological studies and, using our cohort of
10 1,032 North American myasthenia gravis patients, approximated the prevalence of
11 familial myasthenia gravis, compared the characteristics of familial disease with
12 sporadic disease, and assessed the co-morbidity of other autoimmune diseases among
13 patients and among their families.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 **METHODS**

32 **Patient ascertainment**

33 Phenotype information of 1,032 patients diagnosed with myasthenia gravis was
34 obtained from myasthenia gravis clinics at fourteen centers across North America
35 between January 2010 and January 2011.¹⁰ The numbers of myasthenia gravis patients
36 attending each of these clinics was not available for this study. Patients were diagnosed
37 by neurologists specializing in myasthenia gravis. Each myasthenia gravis diagnosis
38 was based on standard clinical criteria that included, but was not limited to, weakness,
39 fatigability, and electrophysiological, pharmacological (edrophonium test) and/or
40 serological abnormalities. Inclusion criteria for this study were as follows: confirmed
41 diagnosis of myasthenia gravis, non-Hispanic white ethnicity, and presence of anti-
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 AChR antibodies. Patients with anti-MuSK antibodies were excluded from the study.
4
5 The LRP4 antibody was discovered after the collection of the cohort was complete.
6
7 Thus, the LRP4 antibody status of the patients was not known. Family histories of
8
9 myasthenia gravis and other autoimmune diseases were systematically obtained for
10
11 each subject using a simple structured questionnaire (Table S1). A positive family
12
13 history was defined as having a first-degree (~50% of DNA in common), second-degree
14
15 (~25% of DNA in common), or third-degree (~12.5% of DNA in common) relative with
16
17 the disease. DNA samples were collected from each subject and used for genetic
18
19 analyses as previously reported.¹⁰ Patients with genetic forms of myasthenia gravis
20
21 were not explicitly excluded, though none of the cohort was known to have such a
22
23 mutation.
24
25
26
27
28
29
30

31 **Literature review methodology**

32
33 To find studies about the epidemiology of familial myasthenia gravis, the PubMed and
34
35 Medline databases were searched using permutations of search terms: 'epidemiology of
36
37 familial myasthenia gravis', 'epidemiology of myasthenia gravis', and 'heritability of
38
39 myasthenia gravis'. After reviewing thirty-one epidemiology studies between the years
40
41 of 1950 through 2018, only ten studies explicitly referenced the family history of
42
43 myasthenic patients. Five of those papers provided metrics about family members with
44
45 myasthenia gravis.¹²⁻¹⁶
46
47
48
49
50

51 **Patient and public involvement statement**

52
53 No patients or members of the public were actively involved with co-producing the
54
55
56
57
58
59
60

1
2
3 research presented in this article.
4
5
6
7

8 **Statement of ethics approval**

9
10 Written informed consent was obtained from all patients who participated in this study.

11
12 Institution review board (IRB) approval was obtained at all participating institutions.

13
14 Lead institutes for IRB = National Institutes of Health, protocol 03-AG-N329,

15
16 <https://clinicaltrials.gov/ct2/show/NCT02014246>
17
18
19
20

21 **Data availability**

22
23 The data, consisting of patient family history of myasthenia gravis and other
24
25 autoimmune diseases in addition to patient personal history of other autoimmune
26
27 diseases, are not publicly available because of patient privacy concerns but de-
28
29 identified participant data are available upon request by contacting the corresponding
30
31 author. In the interests of scientific rigor, the code used for analysis of the dataset is
32
33 available on GitHub: <https://github.com/neurogenetics/Familial-Myasthenia-Gravis>.
34
35
36
37
38
39

40 **RESULTS**

41 **North American cohort of myasthenia gravis patients**

42
43 Clinical data were collected from a total of 1,032 patients across fourteen centers in
44
45 North America and were analyzed in this study. All of the patients had positive anti-
46
47 AChR antibodies. The median age of symptom onset in this clinic-based cohort was 58
48
49 years of age (range = 4-91; median onset age for females = 46; median onset age for
50
51 males = 62). The female-to-male ratio was 1:1.27. Early-onset disease (< 40 years of
52
53
54
55
56
57
58
59
60

1
2
3 age) was observed among 248 (24.0%) of the cohort. Consistent with other reports,
4
5 nearly one third of the patients in our North American study cohort (305, 29.6%) had
6
7 undergone thymectomy.
8
9

10 Fifty-eight (5.6%) patients had a family history of myasthenia gravis. Sibling-
11
12 sibling (31.0%) and parent-child (32.8%) were the most common type of familial
13
14 relationship, followed by uncle/aunt-nephew/niece (13.8%), cousin-cousin (12.1%) and
15
16 grandparent-grandchild (5.2%) relationships. Of note, the indicated percentage of
17
18 parent-child cases might be inflated because neonatal myasthenia gravis cases (which
19
20 are not believed to be genetic) could not be discerned from non-neonatal cases. Age at
21
22 symptom onset was similar among patients with a family history compared to patients
23
24 without a family history (57.5 years of age, range = 8-80 years versus 58.5 years, range
25
26 = 4-91 years, p-value = 0.183, Wilcoxon rank sum test, figure 1, table 1).
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Comparison of familial and sporadic cases among a cohort of patients diagnosed with myasthenia gravis (n = 1,032)

	Familial	Sporadic	P-value
Number of myasthenia gravis cases (percent)	58 (5.6)	974 (94.4)	-
Median age of disease onset (years) (range)	57.5 (8-80)	58.5 (4-91)	0.183
Number of patients with early-onset disease (< 40 years) (percent)	15 (25.9)	233 (23.9)	0.86
Number of females (percent)	25 (43.1)	429 (44.0)	0.997

A personal history of an autoimmune disease other than myasthenia gravis was reported in 275 (26.6%) of study participants. A total of 293 (28.4%) subjects had a family history of an autoimmune disease. The prevalence of autoimmunity in the general population is ~3-9%, indicating that the rates observed among our myasthenia gravis subjects are significantly increased.¹⁷ A breakdown of the specific autoimmune diseases

1
2
3 for both personal history and family history of disease is shown in figure 2A and figure
4
5 2B.
6

7
8 The most common autoimmune diseases present concomitantly in myasthenia
9
10 gravis patients were thyroid disease (n = 118, 11.4%), hematological disease (n = 33,
11
12 3.2% consisting of autoimmune hemolytic anemia and autoimmune thrombocytopenic
13
14 purpura), and rheumatoid arthritis (n=28, 2.7%). This was similar to the rates previously
15
16 reported by Mao et al (figure 2C).¹⁸
17
18

19 The three most common autoimmune diseases present in the families of
20
21 myasthenia gravis patients were thyroid disease (n=98, 9.5%), rheumatoid arthritis
22
23 (n=68, 6.6%), and type 1 diabetes (n=36, 3.5%).
24
25
26
27

28 **Literature review**

29
30 Literature review concerning the epidemiology of familial myasthenia gravis identified
31
32 five studies that discussed the patient's family history of myasthenia gravis with sample
33
34 sizes that ranged from 264 to 6,638 (table 2).¹²⁻¹⁶ The frequency of familial myasthenia
35
36 gravis ranged from 0.2% to 7.2% across studies, the upper limit having been reported
37
38 based on a Finnish cohort.¹⁵ Among these, three studies reported that familial
39
40 myasthenia gravis cases had an earlier symptom onset age than the sporadic cases.^{12,}
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
14, 15 Only three studies reported on the patient history of other autoimmune diseases
and/or on the family history of other autoimmune diseases.^{12, 14, 15} Among these, thyroid
disease, rheumatoid arthritis, systemic lupus erythematosus, and Sjogren's syndrome
were the most common other autoimmune diseases reported in patients' personal
and/or family histories. ^{12, 14, 15}

Table 2. Studies reporting the rate of familial disease in myasthenia gravis.

Source	Origin	Sample size	Familial rate	Study type
12	Taiwan	6,638	0.2%	Population
13	Japan	3,141	0.7%	Population
14	Spain	462	3.5%	Clinic
15	Finland	264	7.2%	Population
16	United States	702	3.8%	Clinic

DISCUSSION

We found the prevalence of familial myasthenia gravis in our North American cohort to be 5.6%. Our previous genetic analysis of this cohort showed the heritability of myasthenia gravis to be 25.5%.¹⁰ This is comparable to the prevalence reported in other studies, where the frequency ranged from 0.2% to 7.2% of myasthenia gravis patients having a family history of myasthenia gravis depending on the cohort studied.¹²⁻¹⁶

Although the vast majority of myasthenia gravis cases are still non-familial, a prevalence of 5.6% represents a several hundred-fold increase for a disease with an overall prevalence of 1 in 5-10,000.⁵ The two studies of myasthenia gravis based on Asian

1
2
3 cohorts reported substantially lower rates of familial disease compared to our North
4 American cohort and other European cohorts. For example, two studies of Taiwanese
5 (n = 6,638) and Japanese (n = 3,141) cohorts reported rates of familial myasthenia
6 gravis at 0.2% and 0.7%, respectively.¹²⁻¹³ Three studies of Spanish, American, and
7 Finnish cohorts reported rates of 3.5%, 3.8%, and 7.2% (table 2).¹⁴⁻¹⁶ The familial rates
8 reported in our cohort of over 1,000 patients were, as expected, closer in value to the
9 rates reported among European and American cohorts. Overall, these data suggest that
10 there is population variation in the inheritance of myasthenia gravis that warrants further
11 study to identify the genetic contribution to disease risk.
12
13
14
15
16
17
18
19
20
21
22
23

24 A notable feature of our cohort is that males had a slightly higher prevalence of
25 familial myasthenia gravis compared to the females (1:1.32), suggesting that there
26 might be sex-specific differences in the occurrence of familial versus sporadic disease.
27 This observation may reflect the different age distribution of myasthenia gravis cases in
28 males versus females observed across all myasthenia gravis cases. The reason for this
29 is unclear, though we note that our previous genome-wide association study of
30 myasthenia gravis indicated that the genetic architecture was different among younger
31 and older age groups.¹⁰
32
33
34
35
36
37
38
39
40
41

42 Myasthenia gravis is an immunological disorder and, generally speaking,
43 autoimmune diseases are known to have heritable components.¹⁹ Likewise,
44 approximately one-third of our cohort had a personal history and/or a family history of
45 another autoimmune disease, which is much higher than the prevalence of 3-9%, which
46 has been historically reported in the general population.¹⁷ We found that 19% (11/58) of
47 the familial myasthenia gravis cases also had a personal history of autoimmune
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 diseases; this was more than the sporadic myasthenia gravis cases in which only 10%
4
5 (98/974) had a personal history of autoimmune diseases. Similar to previous reports, we
6
7 found thyroid disease, rheumatoid arthritis, systemic lupus erythematosus, and type 1
8
9 diabetes to be the most commonly identified comorbidities (figure 2C).^{18, 19} Interestingly,
10
11 the frequency of thyroid disease in this cohort (11.4%) is similar to the frequency range
12
13 of thyroid disease reported in a study by Kiessling et al.²⁰ The increased prevalence of
14
15 familial myasthenia gravis and increased prevalence of other autoimmune disorders
16
17 both suggest that these autoimmune diseases may share a common predisposition that
18
19 may be genetic in origin. We speculate that the link between thyroid disease and
20
21 myasthenia gravis may be due to a common genetic background or an immunological
22
23 cross-reactivity against epitopes or auto-antigens shared by the thyroid and other
24
25 tissues relevant to myasthenia gravis.^{21,22} Future studies focusing on specific genes and
26
27 genomic variants encountered in patients with familial myasthenia gravis offer the
28
29 promise to more precisely identify any genetic contributions to the disease.
30
31
32
33
34

35 While our study has some notable strengths, it also has an inherent limitation
36
37 related to its reliance on self-reported family histories, which could have over- or
38
39 underestimated the prevalence of the diseases studied. For example, it is plausible that
40
41 a patient could self-report as not having a family history of myasthenia gravis because
42
43 the family member was never clinically diagnosed with the disease or did not live long
44
45 enough for the disease to manifest. Similarly, other studies have found an
46
47 overestimation of some autoimmune diseases, especially thyroid disease and
48
49 rheumatoid arthritis, related to self-reporting.²³
50
51
52
53

54 Our analyses provide evidence of a genetic contribution to myasthenia gravis
55
56
57
58
59
60

1
2
3 based on the higher than expected rate of familial disease observed among our North
4
5 American patient cohort, as well as the co-occurrence of autoimmune diseases known
6
7 to have a genetic basis among this population. More work needs to be done to further
8
9 elucidate the genetic etiology of this archetypal autoimmune disease.
10
11
12
13
14
15
16
17
18

19 **ACKNOWLEDGEMENTS**

20
21 This work was supported in part by the Intramural Research Programs of the National
22
23 Institutes of Health National Institute on Aging (Z01-AG000949-02). The work was also
24
25 supported by the Myasthenia Gravis Foundation (Drs Drachman and Traynor), a
26
27 generous bequest by Geraldine Weinrib, and a gift from Philip Swift. Support was
28
29 provided by Mr. and Mrs. Don Brandon and the Department of Neurology, University of
30
31 Kansas Medical Center. The funders had no role in the design and conduct of the study;
32
33 collection, management, analysis, and interpretation of the data; preparation, review, or
34
35 approval of the manuscript; and decision to submit the manuscript for publication. We
36
37 thank the patients and research participants who contributed samples for this study.
38
39
40
41
42
43

44 **Competing interests**

45
46 Mr. Green none declared.

47
48
49 Dr. Barohn served as a consultant for NuFactor and Momenta Pharmaceutical and
50
51 receives research support from PTC Therapeutics, Ra Pharma, Orphazyme, Sanofi
52
53 Genzyme, FDA OOPD, NIH, and PCORI.
54
55
56
57
58
59

1
2
3 Dr. Bartoccion none declared.
4

5 Dr. Benetar reports grant support from Muscular Dystrophy Association, ALS
6 Association, ALS Recovery Fund, Kimmelman Estate, Target ALS, Eli Lilly & Company,
7 and the National Institutes of Health (NIH) during the conduct of the study. He also
8 reports grant support from FDA, CDC, and DOD; research support from Alexion
9 Pharmaceuticals, UCB, Cytokinetics, Neuraltus, Biogen and Orphazyme A/S; and
10 personal fees from NMD Pharma, Ra Pharmaceuticals, Mitsubishi-Tanabe, Avexis,
11 UCB and Denali outside the submitted work.
12
13
14
15
16
17
18
19
20

21 Mr. Blackmore none declared
22

23 Dr. Chaudhry served as a consultant for review and expert testimony for the
24 Department of Health and Human Services and the Department of Justice under the
25 Vaccine Injury and Compensation Program. Dr. Chaudhry has received royalty for total
26 neuropathy score (TNS) patented (through Johns Hopkins University) for license of TNS
27 use from AstraZeneca, Genentech, Seattle Genetics, Calithera Biosciences, Inc,
28 Merrimack Pharmaceuticals, Inc., Levicept, and Acetylon Pharmaceuticals, Inc.
29
30
31
32
33
34
35
36

37 Dr. Chopra none declared.
38

39 Dr. Corse none declared.
40

41 Dr. Dimachkie serves or recently served as a consultant for ArgenX, Catalyst, CSL-
42 Behring, Kezar, Momenta, NuFactor, RMS Medical, Sanofi Genzyme, Shire Takeda,
43 and Spark Therapeutics. Dr. Dimachkie received grants from Alexion, Alnylam
44 Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, CSL-Behring,
45 FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Mitsubishi Tanabe Pharma, MDA,
46 NIH, Novartis, Sanofi Genzyme, Octapharma, Orphazyme, Sarepta Therapeutics, Shire
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Takeda, Spark, UCB Biopharma, Viomed & TMA.
4

5 Dr. Evoli was a member of the advisory board for Alexion, a scientific award jury
6
7 member for Grifols and safety data monitor for UCB.
8

9
10 Dr. Florence none declared.
11

12 Dr. Freimer has received honoraria for serving on advisory boards for ARGNX pharma,
13
14 Alexion. Dr. Freimer also has research support from Catalyyst, Ra pharma, Amicus,
15
16 Orphazyme, Alexion, Momenta and Alnylum.
17

18
19 Dr. Howard reports research support and grants from Alexion Pharmaceuticals, argenx
20
21 BVBA, Centers for Disease Control and Prevention, Muscular Dystrophy Association,
22
23 NIH (including the National Institute of Neurologic Disorders and Stroke and the
24
25 National Institute of Arthritis and Musculoskeletal and Skin Disease), PCORI (Patient-
26
27 Centered Outcomes Research Institute), and Ra Pharmaceuticals; and nonfinancial
28
29 support from Alexion Pharmaceuticals, argenx BVBA, Ra Pharmaceuticals, and
30
31 Toleranzia.
32
33

34
35 Dr. Jiwa none declared.
36

37
38 Dr. Kaminski is funded by the Muscular Dystrophy Association (508240) and by NIH
39
40 grant U54NS115054; is a consultant for Alnylam Pharmaceuticals, Ra Pharmaceuticals,
41
42 and UCB Pharmaceuticals; and is CEO of ARC Biotechnology, LLC, which receives
43
44 support from the NIH (R41NS110331). He serves on the Editorial Board of Experimental
45
46 Neurology.
47

48
49 Dr. Kissel none declared.
50

51
52 Ms. Koopman none declared.
53

54
55 Ms. Lipscomb none declared.
56
57
58
59
60

1
2
3 Dr. Maestri none declared.
4

5 Dr. Marino none declared.
6

7 Dr. Massey none declared
8

9
10 Dr. McVey none declared.
11

12 Dr. Mezei has received honoraria as a speaker and/or moderator from Alnylam, Akcea,
13
14 Pfizer and CSL Behring. She has served on Advisory Boards for Pfizer, Alnylam and
15
16 Akcea. She serves as an investigator for clinical trials with Alnylam and Biogen.
17

18
19 Dr. Muppidi has served on advisory board meetings for Alexion and argenx.
20

21 Dr. Nicolle none declared.
22

23
24 Dr. Oger none declared.
25

26 Dr. Pascuzzi none declared.
27

28 Dr. Pasnoor served on advisory board for CSL Behring, Alexion pharmaceuticals,
29
30 Argenx Pharmaceuticals and has been consultant for Momenta Pharmaceuticals.
31

32
33 Dr. Pestronk none declared.
34

35 Dr. Provenzano none declared.
36

37 Dr. Ricciardi none declared.
38

39
40 Dr. Richman receives research funding from a Sponsored Research Agreement from
41
42 Cabaletta Bioscience.
43

44 Dr. Rowin none declared.
45

46 Dr. Sanders none declared.
47

48
49 Dr. Siddiqi none declared.
50

51 Ms. Soloway none declared
52

53
54 Dr. Wolfe none declared.
55

1
2
3 Dr. Wulf none declared.
4

5 Dr. Drachman none declared.
6

7 Dr. Traynor holds an American and European Union patent on the clinical testing and
8 therapeutic intervention for the hexanucleotide repeat expansion of C9orf72. Has
9 received research grants from The Myasthenia Gravis Foundation, the Robert Packard
10 Center for ALS Research, the ALS Association (ALSA), the Italian Football Federation
11 (FIGC), the Center for Disease Control and Prevention (CDC), the Muscular Dystrophy
12 Association (MDA), Merck Inc., and Microsoft Research. Dr. Traynor receives funding
13 through the Intramural Research Program at the National Institutes of Health.
14
15
16
17
18
19
20
21
22

23 **Funding**

24 Study funding by the National Institutes of Health Intramural Research Program. The
25 work was also supported by the Myasthenia Gravis Foundation (Drs Drachman and
26 Traynor), a generous bequest by Geraldine Weinrib, and a gift from Philip Swift. Support
27 was provided by Mr. and Mrs. Don Brandon and the Department of Neurology,
28 University of Kansas Medical Center.
29
30
31
32
33
34
35
36
37
38
39

40 **References**

- 41
42
43 1. Fambrough DM, Drachman DB, Satyamurti S. Neuromuscular
44 junction in myasthenia gravis: decreased acetylcholine receptors. *Science* 1973;
45 182:293-295.
46
47
48
49 2. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-
50 antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis
51 without acetylcholine receptor antibodies. *Nat Med* 2001;7:365-368.
52
53
54
55
56
57
58
59

- 1
2
3 3. Gasperi C, Melms A, Schoser B, et al. Anti-agrin autoantibodies in myasthenia
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
10 3. Gasperi C, Melms A, Schoser B, et al. Anti-agrin autoantibodies in myasthenia
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
4. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density
lipoprotein receptor-related protein 4 in myasthenia gravis. *Ann Neurol* 2011;69:418-
422.
5. Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia
gravis: a review. *Autoimmune Dis* 2012;2012:874680.
6. McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia gravis: a
systematic literature review. *Neuroepidemiology* 2010;34:171-183.
7. Yu YL, Hawkins BR, Ip MS, Wong V, Woo E. Myasthenia gravis in Hong Kong
Chinese. 1. Epidemiology and adult disease. *Acta Neurol Scand* 1992;86:113-119.
8. MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and
lifetime prevalence of neurological disorders in a prospective community-based study in
the UK. *Brain* 2000;123 (Pt 4):665-676.
9. Spillane J, Higham E, Kullmann DM. Myasthenia gravis. *BMJ* 2012;345:e8497.
10. Renton AE, Pliner HA, Provenzano C, et al. A genome-wide association study of
myasthenia gravis. *JAMA Neurol* 2015;72:396-404.
11. Giraud M, Vandiedonck C, Garchon HJ. Genetic factors in autoimmune
myasthenia gravis. *Ann N Y Acad Sci* 2008;1132:180-192.
12. Liu FC, Kuo CF, See LC, Tsai HI, Yu HP. Familial aggregation of myasthenia
gravis in affected families: a population-based study. *Clin Epidemiol* 2017;9:527-535.
13. Murai H, Yamashita N, Watanabe M, et al. Characteristics of myasthenia gravis
according to onset-age: Japanese nationwide survey. *J Neurol Sci* 2011;305:97-102.

- 1
2
3 14. Salvado M, Canela M, Ponseti JM, et al. Study of the prevalence of familial
4
5 autoimmune myasthenia gravis in a Spanish cohort. *J Neurol Sci* 2016;360:110-114.
6
- 7
8 15. Pirskanen R. Genetic aspects in myasthenia gravis. A family study of 264 Finnish
9
10 patients. *Acta Neurol Scand* 1977;56:365-388.
11
- 12
13 16. Namba T, Brunner NG, Brown SB, Muguruma M, Grob D. Familial myasthenia
14
15 gravis. Report of 27 patients in 12 families and review of 164 patients in 73 families.
16
17 *Arch Neurol* 1971;25:49-60.
18
- 19
20 17. Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of
21
22 autoimmune diseases: improved prevalence estimates and understanding of clustering
23
24 of diseases. *J Autoimmun* 2009;33:197-207.
25
- 26
27 18. Mao ZF, Yang LX, Mo XA, et al. Frequency of autoimmune diseases in
28
29 myasthenia gravis: a systematic review. *Int J Neurosci* 2011;121:121-129.
30
- 31
32 19. Ceccarelli F, Agmon-Levin N, Perricone C. Genetic Factors of Autoimmune
33
34 Diseases. *J Immunol Res* 2016;2016:1-2.
35
- 36
37 20. Kiessling WR, Finke R, Kotulla P, Schleusener H. Circulating TSH-binding
38
39 inhibiting immunoglobulins in myasthenia gravis. *Acta Endocrinol (Copenh)*
40
41 1982;101:41-46.
42
- 43
44 21. Marino M, Ricciardi R, Pinchera A, Barbesino G, Manetti L, Chiovato L,
45
46 Braverman LE, Rossi B, Muratorio A, Mariotti S., Mild Clinical Expression of Myasthenia
47
48 Gravis Associated With Auto-immune Thyroid Diseases. *J Clin Endocrinol Metab.*
49
50 1997;82:438-443. doi: 10.1210/jc.82.2.438
51
52
53
54
55
56
57
58
59
60

- 1
2
3 22. Masood I., Yasir M., Kudyar RP., Autoimmune thyroid disease with myasthenia
4 gravis in a 28-year-old male: a case report. *Cases J.*, 2007;2:8766. doi: 10.4076/1757-
5 1626-2-8766
6
7
8
9
10 23. O'Rourke JA, Ravichandran C, Howe YJ, Mullett JE, Keary CJ, Golas SB,
11 Hureau AR, McCormick M, Chung J, Rose NR, McDougale CJ. Accuracy of self-reported
12 history of autoimmune disease: A pilot study. *PLoS ONE* 2019;14(5): e0216526
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Figures

Figure 1.

Symptom-onset age distribution of sporadic and familial cases. The density represents the relative probability of myasthenia gravis at each age point.

Figure 2.



Autoimmune diseases in a cohort of 1,032 patients with myasthenia gravis. (A) Occurrence of autoimmune diseases among patients with myasthenia (n = 275). (B) Occurrence of autoimmune diseases among familial relatives of patients with myasthenia gravis (n = 293). (C) Comparisons of autoimmune diseases among patients with myasthenia gravis and among relatives. Size of circles represent the percentage previously reported by Mao et al.¹⁸



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

A. Personal history of autoimmune diseases

B. Family history of autoimmune diseases



C. Relationships between personal and family histories of autoimmune diseases




Table S1. Questionnaire used to collect demographic and clinical information from patients diagnosed with myasthenia gravis

Patient Information	
Patient identification number:	String (e.g., JHU1, JHU2)
Institution:	String (e.g., Johns Hopkins, UWO)
Date:	Date
Verified as Caucasian?	Yes/No
AChR titer - Initial or 1st known:	Numeric
Age at symptom onset (years):	Numeric
Gender:	Male/Female
Worst status	
Diplopia or ptosis only?	Yes/No
Mild limb weakness?	Yes/No
Dysphagia dyspnea?	Yes/No
Severe limb weakness?	Yes/No
Hospitalized?	Yes/No
Ventilated?	Yes/No
Feeding tube?	Yes/No
Treatment	
Mestinon?	Yes/No
Benefit: Mestinon:	Ordinal scale [0,1,2]
Prednisone?	Yes/No
Benefit: Prednisone:	Ordinal scale [0,1,2]
CellCept?	Yes/No
Benefit: CellCept?	Ordinal scale [0,1,2]
Cyclosporine?	Yes/No
Benefit: Cyclosporine:	Ordinal scale [0,1,2]
Tacrolimus?	Yes/No
Benefit: Tacrolimus:	Ordinal scale [0,1,2]
Intravenous immunoglobulin?	Yes/No
Benefit: Intravenous immunoglobulin:	Ordinal scale [0,1,2]
Plasmapheresis?	Yes/No
Benefit: Plasmapheresis:	Ordinal scale [0,1,2]
Imuran/Azathioprine?	Yes/No
Benefit: Imuran/Azathioprine:	Ordinal scale [0,1,2]
Other treatment?	Yes/No
Name of other 1:	String (e.g., Mytelase)
Benefit: other 1:	Ordinal scale [0,1,2]
Name of other 2:	String (e.g., Mytelase)
Benefit: other 2:	Ordinal scale [0,1,2]

Best Status	
Back to normal without medication?	Yes/No
Back to normal with medication?	Yes/No
Diplopia or ptosis only?	Yes/No
Mild limb weakness?	Yes/No
Dysphagia/dyspnea?	Yes/No
Severe limb weakness?	Yes/No
Hospitalized?	Yes/No
Ventilated?	Yes/No
Feeding tube:	Yes/No
Other Autoimmune Diseases	
Other autoimmune disease?	Yes/No
Thyroiditis?	Yes/No
Lupus?	Yes/No
Rheumatoid arthritis?	Yes/No
Psoriasis?	Yes/No
Blood disease?	Yes/No
Other Autoimmune Disease?	Yes/No
Other Autoimmune Disease (Name1):	String (e.g., vitiligo, celiac disease)
Other Autoimmune Disease (Name2):	String (e.g., vitiligo, celiac disease)
Other Autoimmune Disease (Name3):	String (e.g., vitiligo, celiac disease)
Family history of myasthenia gravis	
Family history of myasthenia gravis?	Yes/No
Myasthenia gravis (Relationship):	String (e.g., mother, sister)
Family history of other Autoimmune Disease	
Family history of other Autoimmune Disease?	Yes/No
Autoimmune Disease (Relationship):	String (e.g., mother, sister)
Autoimmune Disease (Disease):	String (e.g., polymyalgia, vitiligo)
Family history of other Autoimmune Disease 2nd Member?	Yes/No
Autoimmune Disease (Relationship) 2nd Member:	String (e.g., mother, sister)
Autoimmune Disease (Disease) 2nd Member:	String (e.g., polymyalgia, vitiligo)
Family history of other Autoimmune Disease 3rd Member?	Yes/No
Autoimmune Disease (Relationship) 3rd Member:	String (e.g., mother, sister)
Autoimmune Disease (Disease) 3rd Member:	String (e.g., polymyalgia, vitiligo)
Other relative in study?	Yes/No
Other relative in study id	String (e.g., JHU1, JHU2)
Thymectomy?	Yes/No
Thymoma?	Yes/No
Histology of thymus if known?	String (e.g., Follicular Hyperplasia)

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cohort studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	7-8
Introduction			10-11
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	10-11
Objectives	3	State specific objectives, including any prespecified hypotheses	11
Methods			11-13
Study design	4	Present key elements of study design early in the paper	11
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	11-13
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	11
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	11-13
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	11-13
Bias	9	Describe any efforts to address potential sources of bias	11-13
Study size	10	Explain how the study size was arrived at	11-13
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	11-13
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	14-15
		(b) Describe any methods used to examine subgroups and interactions	14-15
		(c) Explain how missing data were addressed	14-15
		(d) If applicable, explain how loss to follow-up was addressed	14-15
		(e) Describe any sensitivity analyses	NA
Results			13-15

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7,11,14
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	13
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Report numbers of outcome events or summary measures over time	13-15
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13-15
		(b) Report category boundaries when continuous variables were categorized	13-15
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	13-15
Discussion			16-18
Key results	18	Summarise key results with reference to study objectives	16-18
Limitations			17-18
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17-18
Generalisability	21	Discuss the generalisability (external validity) of the study results	17-18
Other information			NA
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	23

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.